

# Curriculum Vitae

## Saro H. Armenian, DO, MPH

**TITLE:** Barron Hilton Chair and Professor of Pediatrics,  
Department of Pediatrics  
Director, Division of Outcomes Research,  
Department of Population Sciences  
Director, Childhood and AYA Cancer Survivorship Program  
Director, Center for Survivorship and Outcomes  
Hematologic Malignancies and Stem Cell Transplantation Institute  
Program Co-Leader, Cancer Control and Population Sciences  
City of Hope Comprehensive Cancer Center

**Business Address** City of Hope  
1500 East Duarte Road  
Duarte, CA 91010-3000  
Telephone: (626) 471-7320  
Fax: (626) 471-9204  
Email: sarmenian@coh.org

### Education

Undergraduate University of Chicago  
Bachelor of Arts  
1992-1996

Medical School Western University of Health Sciences  
College of Osteopathic Medicine of the Pacific  
1998-2002

Internship Department of Pediatrics  
Children's Hospital Los Angeles  
University of Southern California  
2002-2003

Residency Department of Pediatrics  
Children's Hospital Los Angeles  
University of Southern California  
2003-2005

Fellowship Division of Hematology-Oncology  
Children's Hospital Los Angeles  
University of Southern California  
2005-2008

Graduate School Master of Public Health  
Epidemiology/Biostatistics  
Department of Preventive Medicine  
Keck School of Medicine  
University of Southern California  
2006-2007

# Curriculum Vitae

## Saro H. Armenian, DO, MPH

### Licensure

California: 20A8610

### Certification

American Board of Pediatrics (ABP #664575):  
General Pediatrics, certified – 2005  
Pediatric Hematology/Oncology, Recertified – 2021

### Honors and Awards

Frank A. Oski Memorial Lectureship  
American Society of Pediatric Hematology/Oncology, 2023

Barron Hilton Chair in Pediatrics  
City of Hope, 2022

Norman & Sadie Lee Foundation Endowed Professorship in Pediatrics  
City of Hope, 2020

Scholar in Clinical Research  
Leukemia & Lymphoma Society, 2016

Ruby N. Roney Endowment  
For Outstanding Faculty in Cancer Survivorship  
City of Hope, 2012

National Marrow Donor Program Award  
Best Abstract, American Society of Hematology Annual Meeting, 2011

Research Career Development Award  
STOP CANCER Foundation, 2011

Paul Calebresi Clinical Oncology Career Development Award  
City of Hope, 2010

HistoGenetics New Investigator Award  
American Society of Bone Marrow Transplantation, 2010

Faculty Instructor of the Year  
Clinical Investigation Training Program  
City of Hope, 2009 & 2010

Clinical Research Training Institute Fellow  
American Society of Hematology, 2007-2008

Fellow Teacher of the Year  
Children's Hospital Los Angeles, 2006

Della M. Mudd Award  
For effective application of scientific knowledge, perceptiveness in the care  
of children and distinguished qualities of character  
Children's Hospital Los Angeles, 2005

Frances Nunnally Winzer Scholar  
Children's Hospital Los Angeles, 2003

Charles Vowels M.D. Award  
For academic excellence and for exhibiting the qualities of concerned  
patient care, and dedication to clinical teaching  
Western University of Health Sciences, 2002

Department of Pediatrics Award  
Western University of Health Sciences, 2002

# Curriculum Vitae

## Saro H. Armenian, DO, MPH

### **Administrative Responsibilities (City of Hope)**

Chair and Professor, January 2022 – present  
Department of Pediatrics

Professor, December 2019 – present  
Departments of Population Sciences

Program Co-Leader, January 2019 – present  
Cancer Control and Population Sciences, City of Hope Comprehensive Cancer Center

Director, January 2016 – present  
Center for Survivorship and Outcomes, Hematologic Malignancies and Stem Cell Transplantation Institute

Director, December 2014 - present  
Division of Outcomes Research, Department of Population Sciences

Director, December 2014 – present  
Childhood Adolescent and Young Adult Cancer Survivorship Program

Associate Professor, December 2014 – November 2019  
Departments of Pediatrics and Population Sciences

Medical Director, August 2008 – November 2014  
Childhood Cancer Survivorship Clinic

Assistant Professor, August 2008 – November 2014  
Departments of Pediatrics and Population Sciences

### **Membership of Professional Associations**

American Association for Cancer Research  
American College of Cardiology  
American Heart Association  
American Society for Transplantation and Cellular Therapy  
American Society of Clinical Oncology  
American Society of Hematology  
American Society of Pediatric Hematology Oncology  
Children's Oncology Group  
International Society of Pediatric Oncology

### **Editorial Board**

Section Editor (Outcomes Research/Survivorship), *Cancer* (2021 – Present)  
Deputy Editor, *Journal of the American College of Cardiology: CardioOncology* (2020 – 2022)  
Associate Editor, *Pediatric Blood and Cancer* (2016 – 2020)

### **Ad-Hoc Reviewer**

*Acta Oncologica, Annals of Internal Medicine, Annals of Oncology, Biology of Blood and Marrow Transplantation, Blood, BMC Cancer, Bone Marrow Transplantation, British Journal of Cancer, British Journal of Haematology, Cancer, Cancer Epidemiology, Biomarkers & Prevention, Cardiology Research and Practice, Circulation, Clinical Cardiology, European Journal of Pediatrics, European Journal of Cancer, Haematologica, International Journal of Radiation Oncology Biology Physics, Journal of the American Medical Association (JAMA), JAMA-Pediatrics, Journal of Cancer Survivorship, Journal of Clinical Oncology, Journal of General Internal Medicine, Journal of Geriatric Oncology, Journal of Neuroimmunology, Journal of the American College of Cardiology (JACC), JACC-Cardiovascular Imaging, JACC-CardioOncology, Journal of the National Cancer Institute (JNCI), JNCI-Spectrum, Journal of the National Comprehensive Cancer Network, Medicine & Science in Sports & Exercise, Nature Communications, Lancet, Lancet Oncology, Lancet Regional Health, Pediatric Blood & Cancer, Pediatric Hematology Oncology, Pediatric Transplantation, Transplant International.*

# Curriculum Vitae

## Saro H. Armenian, DO, MPH

### **National Grant Review Panels/ Advisory Boards**

#### National Institutes of Health (NIH):

- Radiation Epidemiology Branch site visit (2018)
- R13 Support for Conferences and Scientific Meetings (2021, 2023); Reviewer (Ad Hoc)
- Cancer, Heart, and Sleep Epidemiology Panel-A & B Study Sections (2017-2021); Member (Ad Hoc)

#### Pablove Foundation:

- Scientific Advisory Board (2010-present)
- Board of Directors (2016-2021)
- Board Member, Emeritus (2021-present)

#### St. Baldrick's Foundation

- Grant Review Committee (2012-present)

#### Rally Foundation

- Medical Advisory Board (2013-present)

#### Leukemia & Lymphoma Society

- Scholar in Clinical Research Award Review Committee (2017-present)

#### Children's Cancer Research Fund

- Grant Review Committee (2019-present)

### **International Grant Review Panels/ Advisory Boards**

Cancer Research UK – Grant Review Committee (2014-present)

Swiss Cancer League - Grant Review Committee (2015-present)

Danish Cancer Survivorship Program – Scientific Advisory Board (2017-present)

International Society of Pediatric Oncology – Scientific Review Committee (2017-present)

National Children's Research Center Ireland - Grant Review Committee (2017)

Dutch Cancer Society – Grant Review Committee (2019-present)

Northern Ireland Chest Heart & Stroke – Grant Review Committee (2021)

### **External Committee Membership**

#### Children's Oncology Group:

- Study Chair, ALTE1621: Pharmacologic reversal of ventricular remodeling in childhood cancer survivors at risk for heart failure (2014-present)
- Study Vice Chair, ALTE11C2: Health Effects after Anthracycline and Radiation Therapy (2012-present)
- Study Vice Chair, ALTE16C1: Effects of modern chemotherapy regimens on spermatogenesis and steroidogenesis in adolescent and young adult survivors of osteosarcoma (2016-present)
- Study Committee, ALTE21C1: Assessment of clonal hematopoiesis and its relationship to cardiovascular disease in Hodgkin lymphoma survivors
- Study Committee, ALTE15N2: Late Effects After High- Risk Neuroblastoma (2014-present)
- Study Committee, ALTE1631: A randomized study investigating the effects of a web-based intervention on moderate and vigorous physical activity among children and adolescents with ALL (2016-present)
- Study Committee, ALTE11C1: Longitudinal Assessment of Ovarian Reserve in Adolescents (2012-present)
- Senior Mentor, Cardiovascular-Pulmonary Late Effects Taskforce (2016-present)
- Member, Long-Term Follow-up Guidelines Core Committee (2010-present).
- Chair, Cardiovascular-Pulmonary Late Effects Taskforce (2009-15)
- Chair, Survivorship and Outcomes Committee (2010-2016)

#### American Society of Clinical Oncology:

- Cardiovascular Disease Expert Panel (Co-Chair: 2014-2017)
- Survivorship Guideline Advisory Group (Co-Chair: 2020-2024)

#### International Late Effects of Childhood Cancer Guideline Harmonization Group:

- Co-Chair, Cardiomyopathy Screening Committee (2012-present)
- Co-Chair, Dexrazoxane Guideline Committee (2020–present)

## **Curriculum Vitae** **Saro H. Armenian, DO, MPH**

- Member, Guideline Development Committee (2011-present)
- Member, Pulmonary Dysfunction Screening Committee (2016-present)
- Member, Metabolic Syndrome Working Group (2017-present)
- Member, Obstetric Care/Surveillance Care (2016-2020)

### National Comprehensive Cancer Network Panels:

- Survivorship (2018-present)
- Pediatric Aggressive Mature B-Cell Lymphoma (2018-present)
- Pediatric Hodgkin Lymphoma (2019-present)

### Childhood Cancer Survivor Study:

- Site Principal Investigator (2015-present)
- Executive Committee (2018-present)
- Chronic Disease Working Group (2019-present)
- Chair, Career Development Award Selection Committee (2020-present)
- Chair, Publications Committee (2021-present)

### BMT-Clinical Trials Network:

- Member, Late Effects, Quality of Life, and Economics Committee (2013-2014, 2020-present)

### Pediatric Normal Tissue Effects of Radiation in the Clinic:

- Member, Cardiovascular outcomes working group (Member: 2014-present)

### NIH BMT Late Effects Consensus Conference:

- Co-Chair, Vascular & Metabolic Working Group (2015-2017)

### American College of Cardiology:

- Pediatric and Adolescent Cardio-Oncology Working Group (2016-present)

### International Conference on Long-Term Complications of Treatment of Children and Adolescents with Cancer

- Steering Committee (2017-present)

### American Society of Pediatric Hematology/Oncology:

- Awards Committee (2019-2022)

### National Marrow Donor Program:

- Scientist, Institutional Review Board (2019-present)

### American Society for Transplantation and Cellular Therapy:

- Committee on Awards (2021-present)

### American Heart Association:

- Cardio Oncology Science Subcommittee (2021-present)

### **City of Hope Institutional Committee Membership**

Board of Directors, Beckman Research Institute; Appointed (2022-present)  
Board of Directors, City of Hope Medical Group; Appointed (2022-present)  
Beckman Research Institute Council; Appointed (2022-present)  
Clinical Cancer Committee; Appointed (2021-present)  
Cancer Center Shared Resources Steering Committee; Appointed (2021-present)  
Faculty Senate Executive Committee; Elected (2020-present)  
Cancer Center Leadership Committee; Appointed (2019-present)  
Appointments & Promotions Committee; Appointed (2019-present)  
Research Operations Faculty Advisory Committee; Appointed (2018-present)  
Medical Executive Committee; Elected (2015-present)  
Cancer Protocol Review and Monitoring Committee; Appointed (2011-2020)  
Search Committee for Chair, Department of Pediatrics (2010-2011)

# Curriculum Vitae

## Saro H. Armenian, DO, MPH

### Teaching and mentorship

#### City of Hope

- Clinical Investigation Training Program  
Course Coordinator and Faculty (2008–2016)
- LEAD 3, Faculty Mentor (2021–2022)
- NIH/NCI K-12 Paul Calebresi Clinical Oncology Career Development Award  
Faculty Advisory Committee (2019–present)
- Cancer Research Education and Training Coordination Education Council (2019-present)

#### American College of Cardiology

- Faculty, Annual Course: Advancing Cardiovascular Care of the Oncology Patient (2017-2020)

#### Post-Doctoral Mentorship

- Ellen Chang, MD; Pediatric Hematology Oncology Fellow, Children’s Hospital Los Angeles (2018–present)  
Currently: Assistant Professor, Department of Pediatrics; University of Cincinnati
- Andrew Sy, MD; Pediatric Hematology Oncology Fellow, Children’s Hospital Orange County (2018–2020)  
Currently: Assistant Professor, Department of Pediatrics; Nicklaus Children’s Hospital
- Urshila Durani, MD, MPH; HCT and Cellular Therapy Fellow, City of Hope (2019-2021)  
Currently: Assistant Professor, Department of Hematology; Mayo Clinic
- Nathan Kamel, DrPH; Doctoral Student, Claremont Graduate University (2019–2021)  
Currently: SDC Project Manager, Statistics Administration; Children’s Oncology Group
- Joy Fulbright, MD (2017–present)  
Currently: Director, Adolescent & Young Adult Program; Director, Survive & Thrive Program; Associate Professor of Pediatrics, University of Missouri-Kansas City School of Medicine
- Matthew Ehrhardt, MD, MS (2017–present)  
Currently: Associate Member; Department of Oncology; St. Jude Children’s Research Hospital
- Hari Narayan, MD (2019–present)  
Currently: Assistant Professor; Department of Pediatrics, Division of Cardiology; Rady Children’s Hospital
- Allison Bechtel, DO (2019–present)  
Currently: Assistant Professor; Department of Pediatrics; Wolfson Children’s Hospital
- Mina Sedrak, MD, MS (2019–present)  
Currently: Deputy Director of Clinical Trials, Center for Cancer and Aging; Associate Professor, Department of Medical Oncology & Therapeutics Research; City of Hope
- Faizi Jamal, MD (2019–present)  
Currently: Chief, Division of Cardiology, Department of Medicine; Director, Non-Invasive Cardiology Laboratory; Associate Clinical Professor, Department of Medicine; City of Hope
- Jan Leerink, MD; Doctoral Student, Amsterdam University Medical Centers (2019–present)  
Currently: Fellow, Pediatric Cardiology, Amsterdam University Medical Centers.
- Rusha Bhandari, MD, MS (2020–present)  
Currently: Assistant Professor; Departments of Pediatrics and Population Sciences; City of Hope
- Kyuwan Lee, PhD (2020–present)  
Currently: Assistant Professor; Division of Outcomes Research, Dept. Population Sciences; City of Hope
- June Rhee, MD; Instructor, Stanford Cardiovascular Institute; Stanford University (2020–present)  
Currently: Assistant Professor; Department of Stem Cell Biology and Regenerative Medicine; Division of Cardiology, Department of Medicine; City of Hope

# Curriculum Vitae

## Saro H. Armenian, DO, MPH

### Active Research Support

**NIH/NHLBI: R01 HL150069 (Armenian)**

**02/01/20 – 01/31/25**

Role: Principal Investigator

*Cardiovascular reserve capacity in survivors of hematopoietic cell transplantation*

Major goal: To determine the trajectories of change in cardiovascular reserve capacity in patients undergoing hematopoietic cell transplantation using advanced diagnostic techniques, and to perform detailed phenotyping of patients, focusing on key organ-specific contributors to change over time.

**NIH/NCI: R01 CA249460 (Armenian [PI]/Geller [MPI])**

**04/01/20 – 03/31/25**

Role: Principal Investigator

*Technology-Enabled Activation of Skin Cancer Screening for Hematopoietic Cell Transplantation Survivors and their Primary Care Providers*

Major goal: Randomized trial to improve skin cancer screening in hematopoietic cell transplantation survivors using Bluetooth-enabled digital dermoscopy and real-time diagnostics.

**NIH/NCI: R21 CA261797 (Armenian)**

**07/01/21 – 06/30/23**

Role: Principal Investigator

*Remote monitoring of cardiac function in childhood cancer survivors*

Major goal: Validate a handheld device for assessment of cardiac function in anthracycline-exposed childhood cancer survivors, evaluate its reproducibility at home, and determine the cost-effectiveness of this approach.

**American Heart Association: 869104 (Volpp [PI]/Armenian [MPI])**

**07/01/21 – 06/30/25**

Disparities in Cardio-Oncology Strategically Focused Research Network

Role: Co-Principal Investigator

*Increasing physical activity to improve cardiovascular health in racially diverse cancer survivor communities*

Major goal: Determine the effectiveness of a remotely delivered behaviorally designed gamification intervention to increase physical activity in breast and prostate cancer survivors at high risk for cardiovascular disease.

**LL Foundation (Armenian)**

**07/01/21 – 06/30/23**

Role: Principal Investigator

*Optimizing the Reproductive Health of Adolescent and Young Adult Cancer Patients*

Major goal: Develop a dedicated oncofertility team to identify AYA cancer patients at risk for infertility, and the infrastructure (electronic portal, risk-based referral) to optimize remote counseling and coordination of care.

**Altschul Foundation (Armenian)**

**07/01/16 – 6/30/23**

Role: Principal Investigator

*Heart Failure in Young Cancer Survivors*

Major goal: Support screening and intervention studies to lower the risk of heart failure young cancer survivors.

**LL Foundation (Armenian)**

**06/01/22 – 06/30/24**

Role: Principal Investigator

*Optimizing Outcomes in Adolescent and Young Adult Cancer Patients with Patient Navigation*

Major goal: Develop a dedicated patient navigation team to identify AYA cancer patients at diagnosis at risk for worse psychosocial outcomes, and the infrastructure to optimize counseling and coordination of care.

**Sacchi Foundation (Armenian)**

**08/15/22 – 08/14/25**

Role: Principal Investigator

*Improving Health-Related Quality of Life for High-Risk Young Cancer Patients*

Major: Develop and evaluate the efficacy of a comprehensive intervention to improve the psychosocial well-being of adolescent and young adult cancer patients with advanced stage or relapsed disease.

**NIH/NCI: P30 CA33572 (Rosen)**

**08/01/97 - 11/30/22**

Role: Co-Leader of Cancer Control and Population Science

Cancer Center Support Grant

The Cancer Center Support Grant provides support for administration and infrastructure for the City of Hope Comprehensive Cancer Center.

**Curriculum Vitae**  
**Saro H. Armenian, DO, MPH**

- NIH/NCI: UG1 CA189955-08S3 (Pollock)** **08/01/21 - 07/31/23**  
Role: Project Principal Investigator  
*Echo-Derived Global Longitudinal Strain to Determine the Efficacy of Low-Dose Carvedilol for Heart Failure Prevention in Anthracycline-Exposed Childhood Cancer Survivors*  
Major goal: Support advanced echocardiographic assessment of treatment response in childhood cancer survivors at risk for heart failure enrolled on a randomized placebo-controlled trial (COG ALTE1621).
- NIH/NCI: R01 CA271104 (Su)** **12/01/22 – 11/30/27**  
Role: Co-Investigator  
*Evaluation of a technology assisted intervention for tailoring oncofertility care in adolescent and young adult cancer survivors: a stepped wedge cluster randomized controlled trial*  
Major goal: Evaluate the effectiveness of a remotely delivered fertility care intervention in young cancer patients
- Department of Defense: W81XWH2210665 (Hayashi)** **07/15/22 – 07/14/26**  
Role: Co-Investigator  
*Assessment of Clonal Hematopoiesis and its Relationship to Cardiovascular Disease in Hodgkin Lymphoma Survivors*  
Major goal: Determine the association between clonal hematopoiesis and cardiovascular disease in long-term survivors of Hodgkin lymphoma.
- NIH/NCI: U24 CA055727 (Armstrong)** **05/10/22 – 11/30/27**  
Role: Co-Investigator  
*Childhood Cancer Survivor Study*  
Major goal: Describe long-term complications after reduced intensity treatment for childhood cancer.
- NIH/NCI: R01 CA261793 (Patel)** **07/01/22 – 06/30/27**  
Role: Co-Investigator  
*Leveraging digital health solutions to reduce learning and functional disparities in children with cancer*  
Major goal: To evaluate the ability of a targeted eHealth parent-directed intervention to improve psychosocial behavioral outcomes in the underserved population of childhood leukemia and lymphoma survivors.
- NIH/NCI: R01 CA254955 (Mostoufi-Moab [PI]/McCormack [MPI])** **09/01/21 - 08/31/26**  
Role: Co-Investigator  
*Intensive tailored exercise training with NAD+ precursor supplementation to improve muscle mass and fitness in adolescent and young adult survivors of childhood cancer*  
Major goal: Randomized trial to improve muscle mass and fitness in young cancer survivors
- NIH/NCI: R01 CA248439 (Wolfson)** **03/24/21 - 02/28/26**  
Role: Co-Investigator  
*Predictors of Systemic Exposure to Oral 6MP During Maintenance in Adolescents and Young Adults with Acute Lymphoblastic Leukemia*  
Major goal: To examine the determinants of systemic oral 6MP and its adherence in adolescents and young adults with acute lymphoblastic leukemia.
- NIH/NHLBI: R21 HL152148 (Ky)** **08/01/20 – 07/30/23**  
Role: Co-Investigator  
*The Feasibility of a Biomarker Guided Strategy in Anthracycline Cardiotoxicity*  
Major goal: Determine the feasibility, tolerability, and potential efficacy of a biomarker-guided approach to reduce the risk of cardiotoxicity in patients receiving anthracyclines
- NIH/NCI: U01 CA213140 (Bhatia)** **04/01/19 – 3/31/24**  
Role: Co-Investigator  
*Bone Marrow Transplant Survivor Study-2 (BMTSS-2)*  
Major goal: Describe the burden of morbidity in a large cohort of hematopoietic cell transplant survivors.
- NIH/NHLBI: UG1 HL069278 (Nakamura)** **09/30/01 – 06/30/24**  
Role: Co-Investigator



## Curriculum Vitae Saro H. Armenian, DO, MPH

*City of Hope Core Clinical for Blood and Marrow Transplantation Clinical Trials Network*

Major goal: Conduct large multi-institutional clinical trials to address critically important issues in hematopoietic cell transplantation, furthering understanding of the best treatment approaches.

**NIH/NCI: R01 CA175216 (Shnorhavorian)**

**07/01/16 – 06/30/23**

Role: Co-Investigator

*Effects of Modern Chemotherapy Regimens on Spermatogenesis and Steroidogenesis in Adolescent and Young Adult (AYA) Survivors of Osteosarcoma*

Major goal: Describe the gonadotoxicity associated with chemotherapeutic agents in males undergoing treatment for osteosarcoma.

### **Completed Research Support**

**Children's Hospital Los Angeles Research Career Development Fellowship**

**07/01/07 - 06/30/08**

*Late Cardiac Complications in Hematopoietic Stem Cell Transplant recipients*

Role: Principal investigator

Major Goal: Identify clinical risk factors for late congestive heart failure in long term survivors of hematopoietic cell transplantation.

**NIH/NCI: P30 CA33572 (Friedman)**

**01/01/09 - 01/31/11**

City of Hope Comprehensive Cancer Center Pilot Funding

Role: Study Principal Investigator

*Role of genetic susceptibility anthracycline-related congestive heart failure following hematopoietic cell transplantation*

Major Goal: This proposal aims to identify genetic risk factors associated with therapy-related heart failure by examining selected polymorphisms in genes thought to regulate metabolism and response to anthracyclines.

**Livestrong Foundation (Armenian, Wong)**

**01/01/09 - 03/31/12**

Role: Co-Principal Investigator

*Cost Effectiveness of Cardiac Guidelines for Survivors of Pediatric Cancers*

Major Goal: To explore the cost-effectiveness of the Children's Oncology Group (COG) guidelines related to cardiomyopathy screening frequencies across various age anthracycline and radiation exposure categories.

**ASBMT New Investigator Award (Armenian)**

**06/01/10 - 07/01/12**

Role: Principal Investigator

*Role of Genetic Susceptibility in Cardiovascular Complications Following HCT*

Major goal: To identify genetic risk in cardiovascular complications after hematopoietic cell transplantation.

**Rally Foundation for Childhood Cancer Research (Armenian)**

**05/31/12 – 06/01/13**

Role: Principal Investigator

*Cardiovascular risk reduction in childhood cancer survivors*

Major goal: Develop novel intervention strategies for primary and secondary prevention of cardiovascular disease in survivors of childhood and adolescent cancer.

**The Leukemia and Lymphoma Society (Mittelman)**

**10/01/10 - 09/30/13**

Role: Co-Investigator

*Vitamin D, Fat and Bone Abnormalities in Acute Lymphoblastic Leukemia*

Major goal: To investigate the relationship between the treatment of ALL, subsequent metabolic and hormonal changes in the host, and bone abnormalities such as osteopenia, osteoporosis and avascular necrosis which occur while on treatment or following completion of therapy.

**STOP CANCER Research Career Development Award (Armenian)**

**01/01/11 - 12/31/13**

Role: Principal Investigator

Major goal: Funding support for career development in translational research in clinical oncology. Focus of research is on understanding cardiovascular complications following completion of therapy in children and adults with malignancies.

**Curriculum Vitae**  
**Saro H. Armenian, DO, MPH**

- NIH/NCI: K12 CA001727 (Mortimer)** **01/01/10 - 12/31/13**  
Role: K12-Scholar  
Paul Calebresi Clinical Oncology Career Development Grant  
*Strategies for cardiovascular risk reduction in survivors of childhood and adult-onset cancers*  
Major goal: Funding support for career development in translational research in clinical oncology. Primary goal of project is to develop a randomized pharmacologic intervention for CHF risk reduction in at risk childhood cancer survivors.
- 6031-12 (Armenian)** **10/01/11 - 09/30/14**  
The Leukemia and Lymphoma Society, Translational Research Program  
Role: Principal Investigator  
*Pharmacologic Reversal of Ventricular Remodeling in Childhood Cancer Survivors at Risk for Congestive Heart Failure (PREVENT-CHF)*  
Major goal: Facilitate the development of a pharmacologic intervention for prevention of anthracycline-related congestive heart failure in high-risk childhood cancer survivors.
- Rally Foundation for Childhood Cancer Research (Armenian)** **06/1/14 – 05/31/15**  
Role: Principal Investigator  
*Cardiovascular risk reduction in childhood cancer survivors*  
Major goal: Develop novel intervention strategies for primary and secondary prevention of cardiovascular disease in survivors of childhood and adolescent cancer.
- St. Baldrick's Foundation, Consortium Research Grant (Armenian)** **07/1/11 – 06/30/15**  
Role: Principal Investigator  
*Pharmacologic prevention of heart failure in survivors of childhood cancer*  
Major goal: Develop a pharmacologic intervention for prevention of anthracycline-related congestive heart failure in high-risk childhood cancer survivors.
- NIH/NCI: R21 CA178344 (Armenian)** **08/01/13 - 07/30/15**  
Role: Principal Investigator  
*Anthracycline-related cardiotoxicity in long-term survivors of lymphoma*  
Major goal: Comprehensively evaluate the cardiac health of survivors of lymphoma following autologous HCT or conventional chemotherapy using speckle-strain echocardiography and blood biomarkers of cardiac remodeling; compare findings to matched health controls.
- Caltech-City of Hope Biomedical Research Initiative (Armenian, Gharib)** **08/01/14 - 07/30/15**  
Role: Co-Principal Investigator  
*Novel iPhone-based platform for early detection of cardiac dysfunction in childhood cancer survivors at risk for anthracycline-related heart failure*  
Major goal: To evaluate the utility and accuracy of an iPhone®- and cardiac magnetic resonance-based measures of cardiac function in childhood cancer survivors treated with anthracyclines.
- NIH/NCI: R01 CA139633 (Bhatia)** **01/01/10 – 11/30/15**  
Role: Co-Investigator  
*Role of Genetic Susceptibility in Therapy-related Subsequent Malignancies*  
To explore the role of genetic susceptibility in the development of subsequent malignant neoplasms SMNs by comparing frequencies of at-risk polymorphic alleles in candidate genes between cases/controls.
- NIH/NCI: P30 CA33572 (Rosen)** **03/01/15 - 02/28/16**  
City of Hope Comprehensive Cancer Center Pilot Funding  
Role: Study Principal Investigator  
*Assessment of cardiovascular reserve capacity in survivors of hematopoietic cell transplantation (HCT)*  
Major Goal: Evaluate the feasibility of using a comprehensive screening tool for detection of asymptomatic cardiovascular disease, using non-invasive measures of cardiovascular reserve capacity in HCT survivors.

**Curriculum Vitae**  
**Saro H. Armenian, DO, MPH**

- NIH/NCI: U10 CA180886 (Adamson)** **03/01/10 - 02/28/16**  
Role: Chair, Survivorship and Outcomes Committee; Children's Oncology Group  
Major goal of this committee is to facilitate conduct of Survivorship and Outcomes studies within COG.
- NIH/NCI: R01 CA140245 (Bhatia)** **07/01/10 –05/31/16**  
Role: Co-Investigator  
*Low Dose Tamoxifen in Hodgkin Lymphoma Survivors for Breast Cancer Risk Reduction*  
Major goal: Phase IIb randomized, double-blind, placebo-controlled trial of 5 mg/day tamoxifen to reduce breast cancer risk in long-term female Hodgkin Lymphoma (HL) survivors treated with chest radiation.
- NIH/NCI: R01 CA166559 (Landier, Klosky)** **04/01/12 – 03/31/17**  
Role: Co-Investigator  
*Quadrivalent Human Papillomavirus (HPV) Vaccine in Cancer Survivors*  
Major goal: Describe the prevalence of HPV vaccine initiation in cancer survivors, identify determinants of vaccine refusal, and describe the safety, tolerability, and immunogenicity of the HPV vaccine in this population.
- St. Baldrick's Foundation, Consortium Research Grant (Chow)** **07/01/12 – 06/30/17**  
Role: Co-Investigator  
*Long-term efficacy of Dexrazoxane as a cardioprotectant against anthracycline-related heart failure*  
Major goal: Longitudinal evaluation of efficacy of Dexrazoxane in >10-year survivors of childhood cancer enrolled on 3 randomized clinical trials for T-Cell acute leukemia and Hodgkin lymphoma.
- The Leukemia & Lymphoma Society 6256-13 (Bhatia)** **10/01/12 – 09/30/17**  
Role: Co-Investigator  
*Bone Marrow Transplant Survivor Study-2 (BMTSS-2)*  
Major goal: To describe the burden of morbidity in a large cohort of hematopoietic cell transplant survivors.
- Caltech-City of Hope Biomedical Research Initiative (Armenian)** **02/01/19 – 01/31/20**  
Role: Principal Investigator  
*Handheld Wireless Platform for Detection of Cardiac Dysfunction in Anthracycline-Exposed Cancer Survivors*  
Major goal: To validate the utility and accuracy of an iPhone®- and cardiac magnetic resonance-based measures of cardiac function in cancer survivors treated with anthracyclines.
- American Cancer Society RSG-15-016-01-CPHPS (Chao)** **07/01/15 – 06/30/20**  
Role: Co-Investigator  
*Chronic health conditions in survivors of adolescent and young adult (AYA) cancer*  
Major goal: To provide a detailed characterization of long-term health problems and late effects associated with cancer treatments in survivors of AYA cancer and inform the overall needs for preventive services and interventions in this at-risk population.
- City of Hope-Ludwig Cancer Research-Hilton Foundation Partnership (Armenian)** **03/01/20 – 02/28/21**  
Role: Principal Investigator  
*Novel exercise strategies to improve cardiometabolic health in high-risk patients*  
Major goal: To develop home-based exercise interventions in patients at high risk of cardiometabolic disease.
- Moores Cancer Center Translational Research Award (Narayan[PI]/Armenian[MPI])** **07/01/20 – 06/30/21**  
Role: Co-Principal Investigator  
*Improved Echocardiographic Diagnosis of Anthracycline-Related Cardiac Dysfunction*  
Major goal: To evaluate the utility and accuracy of novel imaging techniques to detection of cardiac dysfunction in anthracycline-exposed long-term childhood cancer.
- NIH/NCI: R01 CA196854 (Armenian)** **07/01/15 – 06/30/21**  
Role: Principal Investigator  
*Reducing risk of anthracycline-related heart failure after childhood cancer*  
Major goal: Test the efficacy of a low dose carvedilol to reduce the thickness-dimension ratio of the heart in asymptomatic childhood cancer survivors with prior exposure to high-dose anthracyclines.

**Curriculum Vitae**  
**Saro H. Armenian, DO, MPH**

**The V Foundation for Cancer Research: DT2019-006 (Armenian)**

**02/01/19 – 01/31/22**

Role: Principal Investigator

*Clonal hematopoiesis and its impact on outcomes after autologous hematopoietic cell transplantation*

Major goal: Examine the impact of clonal somatic mutations in blood on adverse health outcomes after transplantation. This will set the stage for the development of personalized risk assessment strategies and targeted treatments that optimally prevent or manage complications associated with HCT.

**Lymphoma & Leukemia Society Scholar Award: 2315-17 (Armenian)**

**07/01/16 – 12/31/21**

Role: Principal Investigator

*Cardiovascular reserve capacity in survivors of hematopoietic cell transplantation*

Major goal: This application aims to understand the pathogenesis of cardiovascular complications in HCT survivors, utilizing novel and comprehensive assessments of cardiovascular health.

**NIH/NCI: R01 CA193478 (Ness)**

**07/01/16 – 06/30/23**

Role: Co-Investigator

*Web-based Physical Activity Intervention for Children with ALL*

Major goal: Evaluate the efficacy of a web-based physical activity intervention in survivors of childhood acute lymphoblastic leukemia.

**NIH/NHLBI: R21 HL150723 (Ky)**

**07/01/20 – 06/30/23**

Role: Co-Investigator

*Strategies in Cardiotoxicity Risk Reduction with Breast Cancer Therapy*

Major goal: Use validated risk scores to identify high cardiovascular risk breast cancer patients prior to treatment with cardiotoxicity therapy and randomize them to a carvedilol or placebo.

**Publications**

1. **Armenian SH**, Chutuape MA, Stitzer ML. Predictors of discharges against medical advice from a short-term hospital detoxification unit. *Drug and Alcohol Dependence*. 1999 Aug 2; 56(1): 1-8. doi: 10.1016/s0376-8716(99)00027-7. PubMed PMID: 10462086.
2. **Armenian S**, Raffel J, Nugent D, Young G. Painless urethral bleeding: an unusual presentation of von Willebrand disease. *Haemophilia*. 2003 May; 9(3): 332-5. PubMed PMID: 12694526.
3. **Armenian SH**, Singh J, Arrieta AC. Risk factors for mortality resulting from bloodstream infections in a Pediatric Intensive Care Unit. *Pediatr Infect Dis J*. 2005 Apr; 24: 309-314. PubMed PMID: 15818289.
4. **Armenian SH**, Han JY, Dunaway TM, Chruch JA. Safety and immunogenicity of live varicella virus vaccine in children with Human Immunodeficiency Virus type 1. *Pediatr Infect Dis J*. 2006 Apr; 25(4): 368-370. PubMed PMID: 16567993.
5. **Armenian SH**, La Via WV, Siegel SE, Mascarenhas L. Evaluation of persistent pulmonary infiltrates in pediatric oncology patients. *Pediatr Blood Cancer*. 2007 Feb; 48(2): 165-72. PubMed PMID: 16411212.
6. Sano H, Gonzalez-Gomez I, Wu SQ, **Armenian SH**, Jubran RF, Shimada H. A case of composite neuroblastoma composed of histologically and biologically distinct clones. *Pediatr Dev Pathol*. 2007 May-Jun; 10(3): 229-32. PubMed PMID: 17535087.
7. Madigan CE, **Armenian SH**, Malogolowkin MH, Mascarenhas L. Extra-cranial malignant rhabdoid tumors in childhood: The Children's Hospital Los Angeles experience. *Cancer*. 2007 Nov 1; 110(9): 2061-6. PubMed PMID: 17828773.
8. **Armenian SH**, Hoffman JA, Butturini A, Kapoor N, Mascarenhas L. Invasive diagnostic procedures for pulmonary infiltrates in pediatric Hematopoietic Stem Cell Transplant recipients, *Pediatr Transplant*. 2007 Nov; 11(7): 736-42. PubMed PMID: 17910650.
9. **Armenian SH**, Panigrahy A, Murphree AL, Jubran RF. Management of retinoblastoma with proximal optic nerve enhancement on MRI at diagnosis. *Pediatr Blood Cancer*. 2008 Oct; 51(4):479-84. PMID: 18478574.

## Curriculum Vitae Saro H. Armenian, DO, MPH

10. **Armenian SH**, Bhatia S. Cardiovascular disease after hematopoietic cell transplantation – lessons learned. *Haematologica*. 2008 Aug; 93(8):1132-6. PubMed PMID: 18669977.
11. **Armenian SH**, Sun CL, Francisco L, Steinberger J, Kurian S, Wong L, Sharp J, Sposto R, Forman SJ, Bhatia S. Late congestive heart failure (CHF) following hematopoietic cell transplantation. *J Clin Oncol*. 2008 Dec 1; 26(34):5537-43. PubMed PMID: 18809605; PubMed Central PMCID: PMC2651101.
12. **Armenian SH**, Bhatia S. Chronic health conditions in childhood cancer survivors: is it all treatment related – or do genetics play a role? *J Gen Intern Med*. 2009 Nov; 24 Suppl 2:S395-400. PubMed PMID: 19838838; PubMed Central PMCID: PMC2763170.
13. **Armenian SH**, Nash KA, Kapoor N, Franklin J, Gaynon PS, Ross LA, Hoffman JA. Prospective monitoring for invasive aspergillosis using galactomannan and polymerase chain reaction in high risk pediatric patients. *J Pediatr Hematol Oncol*. 2009 Dec; 31(12):920-6. PubMed PMID: 19855303.
14. Baker KS, **Armenian S**, Bhatia S. Long term consequences of hematopoietic stem-cell transplantation: current state of the science. *Biol Blood Marrow Transplant*. 2010 Jan; 16(1 Suppl): S90-6. PubMed PMID: 19782145; PubMed Central PMCID: PMC2832710.
15. **Armenian SH**, Sun CL, Mills G, Berano Teh J, Francisco L, Durand JB, Wong FL, Forman SJ, Bhatia S. Predictors of late cardiovascular complications in survivors of hematopoietic cell transplantation. *Biol Blood Marrow Transplant*. 2010 Aug; 16(8):1138-1144. PMID: 20197101; PMCID: PMC2888883.
16. **Armenian SH**, Sun CL, Berano Teh J, Arora M, Baker KS, Francisco L, Forman SJ, Bhatia S. Ethnic differences in chronic health conditions after hematopoietic cell transplantation: a report from the Bone Marrow Transplant Survivor Study. *Cancer*. 2010 Sep 1; 116(17):4152-9. NIHMSID: NIHMS189758. PubMed PMID: 20564108; PubMed Central PMCID: PMC2930121.
17. Ness KK, **Armenian SH**, Kadan-Lottick N, Gurney J. Adverse effects of treatment in childhood acute lymphoblastic leukemia: implications for long-term cardiac health. *Exp Rev Hematol*. 2011 Apr; 4(2):185-97. PMID: 21495928 PMCID: PMC3125981.
18. **Armenian SH**, Sun CL, Kawashima T, Arora M, Leisenring W, Sklar CA, Baker KS, Francisco L, Teh JB, Mills G, Wong FL, Rosenthal J, Diller L, Hudson MM, Oeffinger KC, Forman SJ, Robison LL, Bhatia S. Long-term outcomes in survivors of childhood cancer treated with hematopoietic cell transplantation (HCT) versus conventional therapy: a report from the Bone Marrow Transplant Survivor Study (BMTSS) and Childhood Cancer Survivor Study (CCSS). *Blood*. 2011 Aug 4; 118(5):1413-20. PubMed PMID: 21652685; PubMed Central PMCID: PMC3152502.
19. Nieder ML, McDonald G, Hingorani S, **Armenian SH**, Cooke KR, Pulsipher MA, Baker KS. National Cancer Institute-National Heart, Lung and Blood Institute/pediatric Blood and Marrow Transplant Consortium First International Consensus Conference on late effects after pediatric hematopoietic cell transplantation: long-term organ damage and dysfunction. *Biol Blood Marrow Transplant*. 2011 Nov; 17(11):1573-84. PubMed PMID: 21963877; PubMed Central PMCID: PMC3215762.
20. **Armenian SH**, Sun CL, Mills G, Shannon T, Francisco L, Venkataraman K, Wong FL, Forman SJ, Bhatia S. Incidence and predictors of congestive heart failure (CHF) after hematologic malignancies treated with autologous hematopoietic cell transplantation (aHCT). *Blood*. 2011 Dec 1; 118(23):6023-9. PubMed Central PMCID: PMC3234663.
21. **Armenian SH**, Sun CL, Francisco L, Arora M, Baker KS, Forman SJ, Bhatia S. Health behaviors and cancer screening practices in long-term survivors of hematopoietic cell transplantation: a report from the Bone Marrow Transplant Survivor Study (BMTSS). *Bone Marrow Transplant*. 2012 Feb; 47(2):283-90. PubMed PMID: 21423125; PubMed Central PMCID: PMC3134636.
22. Pulsipher MA, Skinner R, McDonald G, Hingorani S, **Armenian SH**, Cooke KR, Gracia C, Petryck A, Bhatia S, Bunin N, Nieder ML, Dvorak CC, Sung L, Sanders JE, Kurtzberg J, Baker KS. National Cancer Institute, National Heart, Lung and Blood Institute/Pediatric Blood and Marrow Transplantation Consortium First International Consensus Conference on Late Effects after Pediatric Hematopoietic Cell Transplantation:

## Curriculum Vitae Saro H. Armenian, DO, MPH

- The Need for Pediatric-Specific Long-Term Follow-up Guidelines. *Biol Blood Marrow Transplant*. 2012 Mar; 18(3):334-47. PubMed PMID: 22248713; PubMed Central PMCID: PMC3281504.
23. **Armenian SH**, Gelehrter SK, Chow EJ. Strategies to prevent anthracycline-related congestive heart failure (CHF) in survivors of childhood cancer. *Cardiol Res Pract*. 2012; 2012:713294. PubMed PMID: 22928146; PubMed Central PMCID: PMC3426199.
  24. **Armenian SH**, Sun CL, Shannon T, Ness K, Blum E, Francisco L, Venkataraman K, Samoa R, Wong FL, Forman SJ, Bhatia S. Cardiovascular risk factors in hematopoietic cell transplantation (HCT) survivors: role in development of subsequent cardiovascular disease. *Blood*. 2012 Nov 29; 120(23):4505-12. PubMed PMID: 23034279; PubMed Central PMCID: PMC3512230.
  25. Landier W, **Armenian SH**, Lee J, Thomas O, Wong FL, Francisco L, Herrera C, Kasper C, Wilson K, Zomorodi M, Bhatia S. Yield of screening for long-term complications using the children's oncology group long-term follow-up guidelines. *J Clin Oncol*. 2012 Dec 10; 30(35):4401-8PubMed PMID: 23091100; PubMed Central PMCID: PMC3515770.
  26. **Armenian SH**. Risk factors of cardiovascular disease after hematopoietic cell transplantation. *Clin Adv Hematol Oncol*. 2013. Feb; 11(2):1-2. PMID: 23598912; PMCID: PMC3899888.
  27. **Armenian SH**, Robison LL. Childhood cancer survivorship: an update on evolving paradigms for understanding pathogenesis and screening for therapy-related late effects. *Curr Opin Pediatr*. 2013 Feb; 25(1):16-22. PMID: 23295717 PMCID: PMC3771864.
  28. VanderWalde AM, Sun CL, Laddaran L, Francisco L, **Armenian S**, Berano-Teh J, Wong FL, Popplewell L, Somlo G, Stein A, Nademanee A, Krishnan A, Kogut N, Forman SJ, Bhatia S. Conditional survival after autologous hematopoietic cell transplantation. *Leukemia*. 2013 Apr; 27(5):1139-45. PubMed PMID: 23183426; PubMed Central PMCID: PMC3776451.
  29. Kremer LCM, Mulder RL, Oeffinger KC, Bhatia S, Landier W, Levitt G, Constine LS, Wallace WH, Caron HN, **Armenian SH**, Skinner R, Hudson MM. A worldwide collaboration to harmonize guidelines for the long-term follow-up of childhood and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. *Pediatr Blood Cancer*. 2013; 60(4):543-9. PubMed PMID: 23281199; PubMed Central PMCID: PMC3819170.
  30. **Armenian SH**, Landier W, Hudson MM, Robison LL, Bhatia S. Children's Oncology Group's 2013 Blueprint for research: Survivorship and Outcomes. *Pediatr Blood Cancer*. 2013 Jun; 60(6):1063-8. PubMed PMID: 23255494; PubMed Central PMCID: PMC3799776.
  31. Mascarenhas L, Malogolowkin M, **Armenian SH**, Sposto R, Venkatramani R. A phase I study of oxaliplatin in pediatric patients with relapsed or refractory extracranial non-hematopoietic solid tumors. *Pediatr Blood Cancer*. 2013 Jul; 60(7):1103-7. PubMed PMID: 23335436; PubMed Central PMCID: PMC3815656.
  32. Sun CL, Kersey JH, **Armenian SH**, Baker KS, Weisdorf DJ, Forman S, Bhatia S. Burden of morbidity 10+ years after hematopoietic cell transplantation: a report from the Bone Marrow Transplant Survivor Study. *Biol Blood Marrow Transplant*. 2013 Jul; 19(7):1073-80. PubMed PMID: 23583827; PubMed Central PMCID: PMC3691346.
  33. **Armenian SH**, Ding Y, Mills G, Sun CL, Venkatraman K, Wong FL, Senitzer D, Wang S, Forman SJ, Bhatia S. Genetic susceptibility to anthracycline-related congestive heart failure in survivors of hematopoietic cell transplantation. *Br J Haematol*. 2013 Oct; 163(2):205-13. PubMed PMID: 23927520; PubMed Central PMCID: PMC3795883.
  34. **Armenian SH**, Chow EJ. Cardiovascular disease in survivors of hematopoietic cell transplantation. *Cancer*. 2014 Feb 15; 120(4):469-79. PubMed PMID: 24166350; PubMed Central PMCID: PMC3946330.
  35. Wang X, Liu W, Sun CL, **Armenian SH**, Hakonarson H, Hageman L, Ding Y, Landier W, Blanco JG, Chen L, Quiñones A, Ferguson D, Winick N, Ginsberg JP, Keller F, Neglia JP, Desai S, Sklar CA, Castellino SM, Cherrick I, Dreyer ZE, Hudson MM, Robison LL, Yasui Y, Relling MV, Bhatia S. Hyaluronan synthase 3

## Curriculum Vitae Saro H. Armenian, DO, MPH

- variant and anthracycline-related cardiomyopathy: a report from the children's oncology group. *J Clin Oncol*. 2014 Mar 1; 32(7):647-53. PubMed PMID: 24470002; PubMed Central PMCID: PMC3927733.
36. Wong FL, Bhatia S, Kurian S, Landier W, Francisco L, Leisenring W, Hudson M, Armstrong GT, Mertens A, Stovall M, Yasui Y, Robison LL, Lipshultz SE, **Armenian SH**. Cost-effectiveness of the children's oncology group long-term follow-up screening guidelines for childhood cancer survivors at risk for treatment-related heart failure. *Ann Intern Med*. 2014; May 20; 160:672-83. PubMed PMID: 24842414; PubMed Central PMCID: PMC4073480.
  37. **Armenian SH**, Gelehrter SK, Vase T, Venkatramani R, Landier W, Wilson KD, Herrera C, Reichman L, Menteeer JD, Mascarenhas L, Freyer DR, Venkataraman K, Bhatia S. Carnitine and cardiac dysfunction in childhood cancer survivors treated with anthracyclines. *Cancer Epidemiol Biomarkers Prev*. 2014 Jun; 23(6):1109-14. PubMed PMID: 24718281; PubMed Central PMCID: PMC4053243.
  38. **Armenian SH**, Gelehrter SK, Vase T, Venkatramani R, Landier W, Wilson KD, Herrera C, Reichman L, Menteeer JD, Mascarenhas L, Freyer DR, Venkataraman K, Bhatia S. Screening for cardiac dysfunction in anthracycline-exposed childhood cancer survivors. *Clin Cancer Res*. 2014 Dec 15;20(24):6314-23. PubMed PMID: 24947931; PubMed Central PMCID: PMC4268342.
  39. **Armenian SH**. Improving screening practices in childhood cancer survivors at risk for treatment-related heart failure. *J Clin Oncol*. 2014 Dec 10;32(35):3923-5. PubMed PMID: 25366690.
  40. Landier W, **Armenian SH**, Bhatia S. Late effects of childhood cancer and its treatment. *Pediatr Clin N Am*. 2015 Feb;62(1):275-300. PMID: 25435123.
  41. **Armenian SH**, Hudson MM, Mulder RL, Chen MH, Constine LS, Dwyer M, Nathan P, Shankar S, Sieswerda E, Skinner R, Steinberger J, van Dalen E, van der Pal H, Wallace H, Levitt G, Kremer LC. Recommendations for Cardiomyopathy Surveillance for Survivors of Childhood Cancer: A Report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. *Lancet Oncology*. 2015 Mar;16(3):e123-e136. PMID: 25752563 PMCID: PMC4485458.
  42. **Armenian SH**, Landier L, Francisco L, Herrera C, Mills G, Siyahian A, Supab N, Wilson K, Wolfson J, Horak D, Bhatia S. Long-term pulmonary function in survivors of childhood cancer. *J Clin Oncol*. 2015 May 10;33(14):1592-600. PMID: 25847925 PMCID: PMC4417729.
  43. **Armenian SH**, Kremer LC, Sklar C. Approaches to reduce the long-term burden of treatment-related complications in survivors of childhood cancer. *Am Soc Clin Oncol Educ Book*. 2015;35: 196-204. PubMed PMID: 25993157.
  44. Chow EJ, Asselin BL, Schwartz CL, Doody DR, Leisenring WM, Aggarwal S, Baker KS, Bhatia S, Constine LS, Freyer DR, Lipshultz SE, **Armenian SH**. Late Mortality After Dexrazoxane Treatment: A Report From the Children's Oncology Group. *J Clin Oncol*. 2015 Aug 20;33(24):2639-45. PubMed PMID: 26014292; PubMed Central PMCID: PMC4534526.
  45. Ehrhardt MJ, **Armenian SH**, Fulbright JM. Screening and intervention for treatment-related cardiac dysfunction in childhood cancer survivors. *Future Oncol*. 2015;11(14):2031-4. PubMed PMID: 26198832.
  46. Bhatia S, **Armenian SH**, Armstrong GT, van Dulmen-Den Broeder E, Hawkins M, Kremer LCM, Kuehni CE, Olsen JH, Robison LL, Hudson MM. Collaborative research in childhood cancer survivorship: The current landscape. *J Clin Oncol*. 2015 Sep 20;33(27):3055-64. PMID: 2630489 PMCID: PMC4567704.
  47. Landier W, Chen Y, Namdar G, Francisco L, Wilson K, Herrera C, **Armenian S**, Wolfson JA, Sun CL, Wong FL, Bhatia S. Impact of Tailored Education on Awareness of Personal Risk for Therapy-Related Complications Among Childhood Cancer Survivors. *J Clin Oncol*. 2015 Nov 20;33(33):3887-93. PubMed PMID: 26324371; PubMed Central PMCID: PMC4652012.

## Curriculum Vitae Saro H. Armenian, DO, MPH

48. **Armenian SH**, Wong FL. Screening for Anthracycline-Related Cardiac Dysfunction in Childhood Cancer Survivors: Can Less be More?. *Pediatr Blood Cancer*. 2015 Dec;62(12):2067-8. PubMed PMID: 26230357.
49. Chen R, Palmer JM, Martin P, Tsai N, Kim Y, Chen BT, Popplewell L, Siddiqi T, Thomas SH, Mott M, Sahebi F, **Armenian S**, Leonard J, Nademanee A, Forman SJ. Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma. *Biol Blood Marrow Transplant*. 2015 Dec;21(12):2136-2140. PubMed PMID: 26211987; PubMed Central PMCID: PMC4639410.
50. **Armenian SH**. Anthracycline-Induced Cardiotoxicity in Young Cancer Patients: The Role of Carnitine. *Ann Nutr Metab*. 2016;68 Suppl 3:10-14. PMID: 27931027.
51. Winter S, Buist NR, Longo N, **Armenian SH**, Lopaschuk G, Wasilewska A. Round Table Discussion. *Ann Nutr Metab*. 2016;68 Suppl 3:21-23. PubMed PMID: 27931031.
52. Scott J, **Armenian S**, Giralt S, Moslehi J, Wang T, Jones L. Cardiovascular disease following hematopoietic stem cell transplantation: Pathogenesis, detection, and the cardioprotective role of aerobic training. *Crit Rev Oncol/Hematol*. 2016 Feb;98: 222-34. PMID: 26643524 PMCID: PMC5003053.
53. **Armenian SH**, Bhatia S. Looking back to inform the future: lessons learned from childhood cancer survivors. *Cancer*. 2016 Mar 1;122(5):678-80. PMID: 26764891.
54. Asselin BL, Devidas M, Chen L, Franco VI, Pullen J, Borowitz MJ, Hutchison RE, Ravindranath Y, **Armenian SH**, Camitta BM, Lipshultz SE. Cardioprotection and Safety of Dexrazoxane in Patients Treated for Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Advanced-Stage Lymphoblastic Non-Hodgkin Lymphoma: A Report of the Children's Oncology Group Randomized Trial Pediatric Oncology Group 9404. *J Clin Oncol*. 2016 Mar 10;34(8):854-62. PubMed PMID: 26700126; PMCID: PMC4872007.
55. Wang X, Sun CL, Quiñones-Lombraña A, Singh P, Landier W, Hageman L, Mather M, Rotter JI, Taylor KD, Chen YD, **Armenian SH**, Winick N, Ginsberg JP, Neglia JP, Oeffinger KC, Castellino SM, Dreyer ZE, Hudson MM, Robison LL, Blanco JG, Bhatia S. CELF4 Variant and Anthracycline-Related Cardiomyopathy: A Children's Oncology Group Genome-Wide Association Study. *J Clin Oncol*. 2016 Mar 10;34(8):863-70. PubMed PMID: 26811534; PubMed Central PMCID: PMC5070560.
56. **Armenian SH**, Xu L, Ky B, Sun CL, Farol LT, Pal SK, Douglas PS, Bhatia S, Chao C. Cardiovascular disease among survivors of adult-onset cancer: a community-based retrospective cohort study. *J Clin Oncol*. 2016 Apr 1;34(10):1122-30. PMID: 26834065 PMCID: PMC7357493.
57. Ehrhardt MJ, Fulbright JM, **Armenian SH**. Cardiomyopathy in Childhood Cancer Survivors: Lessons from the Past and Challenges for the Future. *Curr Oncol Rep*. 2016 Apr;18(4):22. PubMed PMID: 26922328.
58. Chow E, Anderson L, Baker KS, Bhatia S, Guilcher GMT, Huang JT, Pelletier W, Perkins JL, Rivard LS, Schechter T, Shah AJ, Wilson KD, Wong K, Grewal S, **Armenian S**, Meacham LR, Mulrooney DA, Castellino SM. Late effects surveillance recommendations among survivors of childhood hematopoietic cell transplantation: a Children's Oncology Group report. *Biol Blood Marrow Transplant*. 2016 May;22(5):782-95. PMID: 26802323 PMCID: PMC4826622.
59. Chao C, Xu L, Bhatia S, Cooper R, Brar S, Wong FL, **Armenian SH**. Cardiovascular Disease Risk Profiles in Survivors of Adolescent and Young Adult (AYA) Cancer: The Kaiser Permanente AYA Cancer Survivors Study. *J Clin Oncol*. 2016 May 10;34(14):1626-33. PMID: 26951318.
60. Arora M, Sun C, Ness KK, Berano Teh J, Wu J, Francisco L, **Armenian SH**, Schad A, Namdar G, Bosworth A, Kuo L, Weisdorf DJ, Forman SJ, Bhatia S. Physiologic frailty in non-elderly hematopoietic cell transplantation survivors: the Bone Marrow Transplant Survivor Study. *JAMA Oncol*. 2016 Oct 1;2(10):1277-1286. PMID: 27254472; PMCID: PMC5078990.
61. van Dorp W, Mulder RL, Kremer LC, Hudson MM, van den Heuvel-Eibrink MM, van den Berg MH, Levine JM, van Dulmen-den Broeder E, di Iorgi N, Albanese A, **Armenian SH**, Bhatia S, Constine LS, Corrias A, Deans R, Dirksen U, Gracia CR, Hjorth L, Kroon L, Lambalk CB, Landier W, Levitt G, Leiper A, Meacham



## Curriculum Vitae Saro H. Armenian, DO, MPH

- L, Mussa A, Neggers SJ, Oeffinger KC, Revelli A, van Santen HM, Skinner R, Toogood A, Wallace WH, Haupt R. Recommendations for Premature Ovarian Insufficiency Surveillance for Female Survivors of Childhood, Adolescent, and Young Adult Cancer: A Report From the International Late Effects of Childhood Cancer Guideline Harmonization Group in Collaboration With the PanCareSurFup Consortium. *J Clin Oncol*. 2016 Oct 1;34(28):3440-50. PMID: 27458300; PMCID: PMC5569686.
62. **Armenian SH**, Hudson MM, Chen MH, Colan SD, Lindenfeld L, Mills G, Siyahian A, Gelehrter S, Dang H, Hein W, Green DM, Robison LL, Wong FL, Douglas PS, Bhatia S. Rationale and design of the Children's Oncology Group (COG) study ALTE1621: a randomized, placebo-controlled trial to determine if low-dose carvedilol can prevent anthracycline-related left ventricular remodeling in childhood cancer survivors at high risk for developing heart failure. *BMC Cardiovasc Disord*. 2016 Oct 4;16(1):187. PMID: 27716152; PMCID: PMC5050602.
63. **Armenian SH**, Chemaitilly W, Chen M, Chow EJ, Duncan CN, Jones LW, Pulsipher MA, Remaley AT, Rovo A, Salooja N, Battiwalla M. National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Cardiovascular Disease and Associated Risk Factors Working Group Report. *Biol Blood Marrow Transplant*. 2017 Feb;23(2):201-210. PMID: 27590105; PMCID: PMC5526451.
64. **Armenian SH**, Lacchetti C, Barac A, Carver J, Constone LS, Denduluri N, Dent S, Douglas PS, Durand JB, Ewer M, Fabian C, Hudson M, Jessup M, Jones LW, Ky B, Mayer EL, Moslehi J, Oeffinger K, Ray K, Ruddy K, Lenihan D. Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline. *J Clin Oncol*. 2017 Mar 10;35(8):893-911. PMID: 27918725.
65. **Armenian SH**, Lacchetti C, Lenihan D. Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline Summary. *J Oncol Pract*. 2017 Apr;13(4):270-275. PubMed PMID: 27922796.
66. **Armenian SH**, Ryan TD, Khouri MG. Cardiac Dysfunction and Heart Failure in Hematopoietic Cell Transplantation Survivors: Emerging Paradigms in Pathophysiology, Screening, and Prevention. *Heart Fail Clin*. 2017 Apr;13(2):337-345. PMID: 28279419.
67. **Armenian SH**, Horak D, Scott JM, Mills G, Siyahian A, Berano Teh J, Douglas PS, Forman SJ, Bhatia S, Jones LW. Cardiovascular Function in Long-Term Hematopoietic Cell Transplantation Survivors. *Biol Blood Marrow Transplant*. 2017 Apr;23(4):700-705. PMID: 28065839; PMCID: PMC5348114.
68. Bhatia S, **Armenian SH**, Landier W. How I monitor long-term and late effects after blood or marrow transplantation. *Blood*. 2017 Sep 14;130(11):1302-1314. PMID: 28743716.
69. Cupit-Link MC, Kirkland JL, Ness KK, Armstrong GT, Tchkonja T, LeBrasseur NK, **Armenian SH**, Ruddy KJ, Hashmi SK. Biology of premature ageing in survivors of cancer. *ESMO Open*. 2017;2(5):e000250. PMID: 29326844; PMCID: PMC5757468.
70. **Armenian SH**, Mertens L, Slorach C, Venkataraman K, Mascarenhas K, Nathwani N, Wong FL, Forman SJ, Bhatia S. Prevalence of anthracycline-related cardiac dysfunction in long-term survivors of adult-onset lymphoma. *Cancer*. 2018 Feb 15;124(4):850-857. PMID: 29112235; PMCID: PMC5801059.
71. Chang HA, **Armenian SH**, Dellinger TH. Secondary Neoplasms of the Female Lower Genital Tract After Hematopoietic Cell Transplantation. *J Natl Compr Canc Netw*. 2018 Feb;16(2):211-218. PMID: 29439180.
72. Wong, JT, **Armenian S**, Nathwani B. A unique pediatric-type follicular lymphoma with extensive marginal zone and monotypic intracytoplasmic plasmacytic differentiation. *Human Pathology: Case Reports*. 2018 March; 11: 25–31.
73. Herrera AF, Palmer J, Martin P, **Armenian S**, Tsai NC, Kennedy N, Sahebi F, Cao T, Budde LE, Mei M, Siddiqi T, Popplewell L, Rosen ST, Kwak LW, Nademanee A, Forman SJ, Chen R. Autologous stem-cell transplantation after second-line brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. *Ann Oncol*. 2018 Mar 1;29(3):724-730. PMID: 29272364; PMCID: PMC5889038.

**Curriculum Vitae**  
**Saro H. Armenian, DO, MPH**

74. **Armenian SH.** Health equity for displaced children with cancer in the Middle East. *Cancer*. 2018 Apr 1;124(7):1322-1325. PMID: 29489014.
75. Al Malki MM, Nathwani N, Yang D, **Armenian S**, Dadwal S, Salman J, Mokhtari S, Cao T, Sandhu K, Rouse M, Mei M, Ali H, Parker P, Alvarnas J, Smith E, Donnell MO, Marcucci G, Snyder D, Nademanee A, Forman SJ, Stein A, Nakamura R. Melphalan-Based Reduced-Intensity Conditioning is Associated with Favorable Disease Control and Acceptable Toxicities in Patients Older Than 70 with Hematologic Malignancies Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. *Biol Blood Marrow Transplant*. 2018 Sep;24(9):1828-1835. PMID: 29753158; PMCID: PMC6163069.
76. **Armenian S**, Bhatia S. Predicting and Preventing Anthracycline-Related Cardiotoxicity. *Am Soc Clin Oncol Educ Book*. 2018 May 23;38:3-12. PMID: 30231396.
77. Maestrini D, Abler D, Adhikarla V, **Armenian S**, Branciamore S, Carlesso N, Kuo YH, Marcucci G, Sahoo P, Rockne RC. Aging in a Relativistic Biological Space-Time. *Front Cell Dev Biol*. 2018;6:55. doi: 10.3389/fcell.2018.00055. eCollection 2018. PMID: 29896473; PMCID: PMC5986934.
78. Holmqvist AS, Chen Y, Wu J, Battles K, Bhatia R, Francisco L, Hageman L, Kung M, Ness E, Parman M, Salzman D, Winther JF, Rosenthal J, Forman SJ, Weisdorf DJ, Arora M, **Armenian SH**, Bhatia S. Late mortality after autologous blood or marrow transplantation in childhood: a Blood or Marrow Transplant Survivor Study-2 report. *Blood*. 2018 Jun 14;131(24):2720-2729. PMID: 29661789; PMCID: PMC6032893.
79. **Armenian SH**, Rinderknecht D, Au K, Lindenfeld L, Mills G, Siyahian A, Herrera C, Wilson K, Venkataraman K, Mascarenhas K, Tavallali P, Razavi M, Pahlevan N, Detterich J, Bhatia S, Gharib M. Accuracy of a Novel Handheld Wireless Platform for Detection of Cardiac Dysfunction in Anthracycline-Exposed Survivors of Childhood Cancer. *Clin Cancer Res*. 2018 Jul 1;24(13):3119-3125. PMID: 29929955.
80. Hudson MM, **Armenian SH**, Armstrong GT, Chow EJ, Henderson TO. Optimization of Health and Extension of Lifespan Through Childhood Cancer Survivorship Research. *J Clin Oncol*. 2018 Jul 20;36(21):2133-2134. PMID: 29874131.
81. **Armenian SH**, Armstrong GT, Aune G, Chow EJ, Ehrhardt MJ, Ky B, Moslehi J, Mulrooney DA, Nathan PC, Ryan TD, van der Pal HJ, van Dalen EC, Kremer LCM. Cardiovascular Disease in Survivors of Childhood Cancer: Insights Into Epidemiology, Pathophysiology, and Prevention. *J Clin Oncol*. 2018 Jul 20;36(21):2135-2144. PMID: 29874141; PMCID: PMC6804893.
82. **Armenian SH**, Yang D, Teh JB, Atencio LC, Gonzales A, Wong FL, Leisenring WM, Forman SJ, Nakamura R, Chow EJ. Prediction of cardiovascular disease among hematopoietic cell transplantation survivors. *Blood Adv*. 2018 Jul 24;2(14):1756-1764. PMID: 30037802; PMCID: PMC6058239.
83. Scott JM, Li N, Liu Q, Yasui Y, Leisenring W, Nathan PC, Gibson T, **Armenian SH**, Nilsen TS, Oeffinger KC, Ness KK, Adams SC, Robison LL, Armstrong GT, Jones LW. Association of Exercise With Mortality in Adult Survivors of Childhood Cancer. *JAMA Oncol*. 2018 Oct 1;4(10):1352-1358. PMID: 29862412; PMCID: PMC6181767.
84. Holmqvist AS, Chen Y, Wu J, Kung M, Ness E, Parman M, Francisco L, Hageman L, Battles K, Bhatia R, Salzman D, Winther JF, Rosenthal J, Forman SJ, Weisdorf DJ, **Armenian SH**, Arora M, Bhatia S. Late mortality after allogeneic blood or marrow transplantation in childhood for leukemia: a report from the Blood or Marrow Transplant Survivor Study-2. *Leukemia*. 2018 Dec;32(12):2706-2709. PMID: 29946190.
85. Holmqvist AS, Chen Y, Wu J, Battles K, Bhatia R, Francisco L, Hageman L, Kung M, Ness E, Parman M, Salzman D, Wadhwa A, Winther JF, Rosenthal J, Forman SJ, Weisdorf DJ, **Armenian SH**, Arora M, Bhatia S. Assessment of Late Mortality Risk After Allogeneic Blood or Marrow Transplantation Performed in Childhood. *JAMA Oncol*. 2018 Dec 1;4(12):e182453. PMID: 30054602; PMCID: PMC6440718.
86. Wadhwa A, Chen Y, Holmqvist A, Wu J, Ness E, Parman M, Kung M, Hageman L, Francisco L, Braunlin E, Miller W, Lund T, **Armenian S**, Arora M, Orchard P, Bhatia S. Late Mortality after Allogeneic Blood or Marrow Transplantation for Inborn Errors of Metabolism: A Report from the Blood or Marrow Transplant Survivor Study-2 (BMTSS-2). *Biol Blood Marrow Transplant*. 2019 Feb;25(2):328-334. PMID: 30292746.

**Curriculum Vitae**  
**Saro H. Armenian, DO, MPH**

87. **Armenian SH**, Ehrhardt MJ. Optimizing Cardiovascular Care in Children With Acute Myeloid Leukemia to Improve Cancer-Related Outcomes. *J Clin Oncol*. 2019 Jan 1;37(1):1-6. PMID: 30422740.
88. Holmqvist AS, Chen Y, Wu J, Battles K, Francisco L, Hageman L, Kung M, Ness E, Parman M, Winther JF, Rosenthal J, Arora M, **Armenian SH**, Bhatia S. Late Mortality after Allogeneic Bone Marrow Transplantation in Childhood for Bone Marrow Failure Syndromes and Severe Aplastic Anemia. *Biol Blood Marrow Transplant*. 2019 Apr;25(4):749-755. PMID: 30578940.
89. **Armenian SH**, Gibson CJ, Rockne RC, Ness KK. Premature Aging in Young Cancer Survivors. *J Natl Cancer Inst*. 2019 Mar 1;111(3):226-232. PMID: 30715446.
90. Chow EJ, Leger KJ, Bhatt NS, Mulrooney DA, Ross CJ, Aggarwal S, Bansal N, Ehrhardt MJ, **Armenian SH**, Scott JM, Hong B. Paediatric cardio-oncology: epidemiology, screening, prevention, and treatment. *Cardiovasc Res*. 2019 Apr 15;115(5):922-934. PMID: 30768157; PMCID: PMC6452306.
91. Gangaraju R, Chen Y, Hageman L, Wu J, Francisco L, Kung M, Ness E, Parman M, Weisdorf DJ, Forman SJ, Arora M, **Armenian SH**, Bhatia S. Late mortality in blood or marrow transplant survivors with venous thromboembolism: report from the Blood or Marrow Transplant Survivor Study. *Br J Haematol*. 2019 Jul;186(2):367-370. PMID: 30883690; PMCID: PMC7768906.
92. **Armenian SH**, Xiao M, Berano Teh J, Lee B, Chang HA, Mascarenhas K, Lee S, Iukuridze A, Xie JJ, Scott JM, Jones LW, Lennie Wong F, Forman SJ, Nakamura R. Impact of Sarcopenia on Adverse Outcomes After Allogeneic Hematopoietic Cell Transplantation. *J Natl Cancer Inst*. 2019 Aug 1;111(8):837-844. PMID: 30951603; PMCID: PMC6695315.
93. D'Amico BG, Finkelman BS, Hubbard RA, Zhang L, Smith AM, Shelton K, McDonald C, Narayan HK, Narayan V, Waxman AJ, Domchek SM, DeMichele A, Shah P, Clark AS, Bradbury AR, Carver JR, Upshaw J, **Armenian SH**, Liu P, Ky B. Detailed phenotyping reveals distinct trajectories of cardiovascular function and symptoms with exposure to modern breast cancer therapy. *Cancer*. 2019 Aug 15;125(16):2762-2771. PMID: 31042319; PMCID: PMC6722325.
94. Chao C, Bhatia S, Xu L, Cannavale KL, Wong FL, Huang PS, Cooper R, **Armenian SH**. Incidence, Risk Factors, and Mortality Associated With Second Malignant Neoplasms Among Survivors of Adolescent and Young Adult Cancer. *JAMA Netw Open*. 2019 Jun 5;2(6):e195536. PMID: 31173129; PMCID: PMC6563559.
95. Gangaraju R, Chen Y, Hageman L, Wu J, Francisco L, Battles K, Kung M, Ness E, Parman M, Weisdorf DJ, Forman SJ, Arora M, **Armenian SH**, Bhatia S. Venous Thromboembolism in Autologous Blood or Marrow Transplantation Survivors: A Report from the Blood or Marrow Transplant Survivor Study. *Biol Blood Marrow Transplant*. 2019 Nov;25(11):2261-2266. PMID: 31278995; PMCID: PMC6861676.
96. Narayan HK, Putt ME, Kosaraju N, Paz A, Bhatt S, Plappert T, Mercer-Rosa L, **Armenian SH**, Desai AV, Womer RB, Ky B. Dexrazoxane preferentially mitigates doxorubicin cardiotoxicity in female children with sarcoma. *Open Heart*. 2019;6(1):e001025. PubMed PMID: 31297226; PMCID: PMC6593195.
97. Sanft T, Denlinger CS, **Armenian S**, Baker KS, Broderick G, Demark-Wahnefried W, Friedman DL, Goldman M, Hudson M, Khakpour N, Koura D, Lally RM, Langbaum TS, McDonough AL, Melisko M, Mooney K, Moore HCF, Moslehi JJ, O'Connor T, Overholser L, Paskett ED, Peterson L, Pirl W, Rodriguez MA, Ruddy KJ, Smith S, Syrjala KL, Tevaarwerk A, Urba SG, Zee P, McMillian NR, Freedman-Cass DA. NCCN Guidelines Insights: Survivorship, Version 2.2019. *J Natl Compr Canc Netw*. 2019 Jul 1;17(7):784-794. PMID: 31319383; PMCID: PMC7094216.
98. Minasian L, Dimond E, Davis M, Adhikari B, Fagerstrom R, Fabian C, Floyd J, Unger JM, Douglas PS, Mustian KM, Chow EJ, Lipshultz S, Hundley WG, **Armenian S**, Ky B. The Evolving Design of NIH-Funded Cardio-Oncology Studies to Address Cancer Treatment-Related Cardiovascular Toxicity. *JACC CardioOncol*. 2019 Sep;1(1):105-113. PMID: 32529192; PMCID: PMC7288847.
99. Wu J, Chen Y, Hageman L, Francisco L, Ness EC, Parman M, Kung M, Watson JA, Weisdorf DJ, Snyder DS, McGlave PB, Forman SJ, Arora M, **Armenian SH**, Bhatia R, Bhatia S. Late mortality after bone marrow transplant for chronic myelogenous leukemia in the context of prior tyrosine kinase inhibitor exposure: A

## Curriculum Vitae Saro H. Armenian, DO, MPH

- Blood or Marrow Transplant Survivor Study (BMTSS) report. *Cancer*. 2019 Nov 15;125(22):4033-4042. PMID: 31412155.
100. Slavin TP, Teh JB, Weitzel JN, Peng K, Wong FL, Qin H, Wang J, Wu X, Mei M, Pillai R, Wang Y, Tsang KK, Pozhitkov A, Krishnan A, Forman SJ, **Armenian SH**. Association between Clonal Hematopoiesis and Late Nonrelapse Mortality after Autologous Hematopoietic Cell Transplantation. *Biol Blood Marrow Transplant*. 2019 Dec;25(12):2517-2521. PMID: 31445185; PMCID: PMC7192097.
  101. Lenihan DJ, Fradley MG, Dent S, Brezden-Masley C, Carver J, Filho RK, Neilan TG, Blaes A, Melloni C, Herrmann J, **Armenian S**, Thavendiranathan P, Armstrong GT, Ky B, Hajjar L. Proceedings From the Global Cardio-Oncology Summit: The Top 10 Priorities to Actualize for CardioOncology. *JACC CardioOncol*. 2019 Dec;1(2):256-272. PMID: 34396188; PMCID: PMC8352295.
  102. Howard E, Steingart RM, Armstrong GT, Lyon AR, **Armenian SH**, Teresa Voso M, Cicconi L, Coco FL, Minotti G. Cardiovascular events in cancer survivors. *Semin Oncol*. 2019 Dec;46(6):426-432. PMID: 31791551.
  103. **Armenian SH**, Jurczak W, Carver JR, Gennari A, Minotti G, Ewer MS. Helping the cardio-oncologist: from real life to guidelines. *Semin Oncol*. 2019 Dec;46(6):433-436. PMID: 31784041.
  104. Gangaraju R, Chen Y, Hageman L, Wu J, Francisco L, Kung M, Ness E, Parman M, Weisdorf DJ, Forman SJ, Arora M, **Armenian SH**, Bhatia S. Risk of venous thromboembolism in patients with non-Hodgkin lymphoma surviving blood or marrow transplantation. *Cancer*. 2019 Dec 15;125(24):4498-4508. PMID: 31469420; PMCID: PMC6891120.
  105. Farrukh N, Hageman L, Chen Y, Wu J, Ness E, Kung M, Francisco L, Parman M, Landier W, Arora M, **Armenian S**, Bhatia S, Williams GR. Pain in older survivors of hematologic malignancies after blood or marrow transplantation: A BMTSS report. *Cancer*. 2020 Jan 1;126(9):2003-2012. PMID: 32022263; PMCID: PMC7263023.
  106. Salhotra A, Hui S, Yang D, Mokhtari S, Mei M, Al Malki MM, Aldoss I, Ali H, Sandhu KS, Aribi A, Khaled S, Dandapani S, Peng K, Teh JB, Murata-Collins J, Budde E, Dadwal S, Pullarkat V, Snyder D, Spielberger R, Wong J, **Armenian S**, Marcucci G, Forman SJ, Nakamura R, Stein A. Long-Term Outcomes of Patients with Acute Myelogenous Leukemia Treated with Myeloablative Fractionated Total Body Irradiation TBI-Based Conditioning with a Tacrolimus- and Sirolimus-Based Graft-versus-Host Disease Prophylaxis Regimen: 6-Year Follow-Up from a Single Center. *Biol Blood Marrow Transplant*. 2020 Feb;26(2):292-299. PMID: 31536825; PMCID: PMC9129102.
  107. Curigliano G, Lenihan D, Fradley M, Ganatra S, Barac A, Blaes A, Herrmann J, Porter C, Lyon AR, Lancellotti P, Patel A, DeCara J, Mitchell J, Harrison E, Moslehi J, Witteles R, Calabro MG, Orecchia R, de Azambuja E, Zamorano JL, Krone R, Iakobishvili Z, Carver J, **Armenian S**, Ky B, Cardinale D, Cipolla CM, Dent S, Jordan K. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. *Ann Oncol*. 2020 Feb;31(2):171-190. PMID: 31959335; PubMed PMCID: PMC8019325.
  108. Border WL, Sachdeva R, Stratton KL, **Armenian SH**, Bhat A, Cox DE, Leger KJ, Leisenring WM, Meacham LR, Sadak KT, Sivanandam S, Nathan PC, Chow EJ. Longitudinal Changes in Echocardiographic Parameters of Cardiac Function in Pediatric Cancer Survivors. *JACC CardioOncol*. 2020 Mar;2(1):26-37. PMID: 32719829; PMCID: PMC7384713.
  109. **Armenian SH**, Xu L, Cannavale KL, Wong FL, Bhatia S, Chao C. Cause-specific mortality in survivors of adolescent and young adult cancer. *Cancer*. 2020 May 15;126(10):2305-2316. doi: PMID: 32129881.
  110. Chang E, Iukuridze A, Echevarria M, Teh JB, Chanson D, Ky B, Chow EJ, Nakamura R, Lindenfeld L, **Armenian SH**. Feasibility and Acceptability of Using a Telehealth Platform to Monitor Cardiovascular Risk Factors in Hematopoietic Cell Transplantation Survivors at Risk for Cardiovascular Disease. *Biol Blood Marrow Transplant*. 2020 Jun;26(6):1233-1237. PMID: 32171884.

**Curriculum Vitae**  
**Saro H. Armenian, DO, MPH**

111. Arora M, Chen Y, Hageman L, Wu J, Landier W, Francisco L, Kung M, Ness E, Bosworth A, Pamukcuoglu M, Weisdorf DJ, Forman SJ, **Armenian SH**, Bhatia S. Morbidity burden in survivors of multiple myeloma who underwent autologous transplantation: A Bone Marrow Transplantation Survivor Study. *Cancer*. 2020 Jul 15;126(14):3322-3329. PMID: 32413187.
112. **Armenian SH**, Iukuridze A, Teh JB, Mascarenhas K, Herrera A, McCune JS, Zain JM, Mostoufi-Moab S, McCormack S, Slavin TP, Scott JM, Jones LW, Sun CL, Forman SJ, Wong FL, Nakamura R. Abnormal body composition is a predictor of adverse outcomes after autologous haematopoietic cell transplantation. *J Cachexia Sarcopenia Muscle*. 2020 Aug;11(4):962-972. PMID: 32212263; PMCID: PMC7432567.
113. Mascarenhas K, Teh JB, Peng K, Kim H, Sy A, Forman SJ, Wong FL, Nakamura R, Dadwal SS, **Armenian SH**. Efficacy of low-dose zoster prophylaxis in patients undergoing allogeneic hematopoietic cell transplantation. *Bone Marrow Transplant*. 2020 Aug;55(8):1662-1664. PMID: 31616064; PMCID: PMC7391285.
114. Denlinger CS, Sanft T, Moslehi JJ, Overholser L, **Armenian S**, Baker KS, Broderick G, Demark-Wahnefried W, Friedman DL, Goldman M, Henry NL, Hill-Kayser C, Hudson M, Khakpour N, Koura D, McDonough AL, Melisko M, Mooney K, Moore HCF, Moryl N, O'Connor T, Paskett ED, Patel C, Peterson L, Pirl W, Rodriguez MA, Ruddy KJ, Shockney L, Smith S, Syrjala KL, Tevaarwerk A, Zee P, McMillian NR, Freedman-Cass DA. NCCN Guidelines Insights: Survivorship, Version 2.2020. *J Natl Compr Canc Netw*. 2020 Aug;18(8):1016-1023. PMID: 32755975; PMCID: PMC7785060.
115. Davies K, Barth M, **Armenian S**, Audino AN, Barnette P, Cuglievan B, Ding H, Ford JB, Galardy PJ, Gardner R, Hanna R, Hayashi R, Kovach AE, Machnitz AJ, Maloney KW, Marks L, Page K, Reilly AF, Weinstein JL, Xavier AC, McMillian NR, Freedman-Cass DA. Pediatric Aggressive Mature B-Cell Lymphomas, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw*. 2020 Aug;18(8):1105-1123. PMID: 32755986.
116. **Armenian SH**, Lindenfeld L, Iukuridze A, Echevarria M, Bebel S, Coleman C, Nakamura R, Abdullah F, Modi B, Oeffinger KC, Emmons KM, Marghoob AA, Geller AC. Technology-enabled activation of skin cancer screening for hematopoietic cell transplantation survivors and their primary care providers (TEACH). *BMC Cancer*. 2020 Aug 3;20(1):721. PMID: 32746799; PMCID: PMC7397711.
117. Narayan HK, Xu R, Forsch N, Govil S, Iukuridze D, Lindenfeld L, Adler E, Hegde S, Tremoulet A, Ky B, **Armenian S**, Omens J, McCulloch AD. Atlas-based measures of left ventricular shape may improve characterization of adverse remodeling in anthracycline-exposed childhood cancer survivors: a cross-sectional imaging study. *Cardiooncology*. 2020;6:13. eCollection 2020. PMID: 32782827.
118. Chao C, Bhatia S, Xu L, Cannavale KL, Wong FL, Huang PS, Cooper R, **Armenian SH**. Chronic Comorbidities Among Survivors of Adolescent and Young Adult Cancer. *J Clin Oncol*. 2020 Sep 20;38(27):3161-3174. PMID: 32673152; PMCID: PMC7499612.
119. McDonald AM, Chen Y, Wu J, Hageman L, Francisco L, Kung M, Wong FL, Ness E, Landier W, Battles K, Salzman D, Weisdorf DJ, Forman SJ, Arora M, **Armenian SH**, Bhatia S. Total Body Irradiation and Risk of Breast Cancer After Blood or Marrow Transplantation: A Blood or Marrow Transplantation Survivor Study Report. *J Clin Oncol*. 2020 Sep 1;38(25):2872-2882. PMID: 32673169; PMCID: PMC7460149.
120. Rhee JW, Ky B, **Armenian SH**, Yancy CW, Wu JC. Primer on Biomarker Discovery in Cardio-Oncology: Application of Omics Technologies. *JACC CardioOncol*. 2020 Sep;2(3):379-384. PMID: 33073248; PMCID: PMC7560982.
121. Wong FL, Teh JB, Atencio L, Stiller T, Kim H, Chanson D, Forman SJ, Nakamura R, **Armenian SH**. Conditional Survival, Cause-Specific Mortality, and Risk Factors of Late Mortality After Allogeneic Hematopoietic Cell Transplantation. *J Natl Cancer Inst*. 2020 Nov 1;112(11):1153-1161. PMID: 32044955; PMCID: PMC7669225.
122. Ehrhardt MJ, Ward ZJ, Liu Q, Chaudhry A, Nohria A, Border W, Fulbright JM, Mulrooney DA, Oeffinger KC, Nathan PC, Leisenring WM, Constine LS, Gibson TM, Chow EJ, Howell RM, Robison LL, Armstrong

## Curriculum Vitae Saro H. Armenian, DO, MPH

- GT, Hudson MM, Diller L, Yasui Y, **Armenian SH**, Yeh JM. Cost-Effectiveness of the International Late Effects of Childhood Cancer Guideline Harmonization Group Screening Guidelines to Prevent Heart Failure in Survivors of Childhood Cancer. *J Clin Oncol*. 2020 Nov 20;38(33):3851-3862. PMID: 32795226; PMCID: PMC7676889.
123. van der Kooi ALF, Mulder RL, Hudson MM, Kremer LCM, Skinner R, Constine LS, van Dorp W, van Dulmen-den Broeder E, Winther JF, Wallace WH, Waugh J, Woodruff TK, Anderson RA, **Armenian SH**, Bloemenkamp KWM, Critchley HOD, Demoor-Goldschmidt C, Ehrhardt MJ, Green DM, Grobman WA, Iwahata Y, Krishna I, Laven JSE, Levitt G, Meacham LR, Miller ES, Mulders A, Polanco A, Ronckers CM, Samuel A, Walwyn T, Levine JM, van den Heuvel-Eibrink MM. Counseling and surveillance of obstetrical risks for female childhood, adolescent, and young adult cancer survivors: recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group. *Am J Obstet Gynecol*. 2021 Jan;224(1):3-15. PMID: 32502557.
124. Bhatia S, Palomares MR, Hageman L, Chen Y, Landier W, Smith K, Umphrey H, Reich CA, Zamora KW, **Armenian SH**, Bevers TB, Blaes A, Henderson T, Hodgson D, Hudson MM, Korde LA, Melin SA, Merajver SD, Overholser L, Pruthi S, Wong FL, Garber JE. A Randomized Phase IIb Study of Low-dose Tamoxifen in Chest-irradiated Cancer Survivors at Risk for Breast Cancer. *Clin Cancer Res*. 2021 Feb 15;27(4):967-974. PMID: 33272980; PMCID: PMC7887034.
125. Pawlowska AB, Karras NA, Liu H, DiMundo J, Cheng JC, Sun W, **Armenian S**, Yang D, Palmer JM, Bell A, Tahoun A, Tegtmeier B, Dadwal S, Rosenthal J. Reactivation of human herpesvirus 6 in pediatric allogeneic hematopoietic stem cell transplant recipients. *Transpl Infect Dis*. 2021 Feb;23(1):e13453. doi: 10.1111/tid.13453. Epub 2020 Sep 22. PubMed PMID: 32860467.
126. Sachdeva R, Stratton KL, Cox DE, **Armenian SH**, Bhat A, Border WL, Leger KJ, Leisenring WM, Meacham LR, Sadak KT, Narasimhan S, Chow EJ, Nathan PC. Challenges associated with retrospective analysis of left ventricular function using clinical echocardiograms from a multicenter research study. *Echocardiography*. 2021 Feb;38(2):296-303. PMID: 33486820; PMCID: PMC8917905.
127. Arora M, Chen Y, Wu J, Hageman L, Ness E, Kung M, Francisco L, Bosworth A, Weisdorf DJ, Forman SJ, Landier W, Pamukçuoğlu M, **Armenian SH**, Wong FL, Bhatia S. Longitudinal trajectory of frailty in blood or marrow transplant survivors: Report from the Blood or Marrow Transplant Survivor Study. *Cancer*. 2021 Mar 1;127(5):794-800. PMID: 33206383; PMCID: PMC8833138.
128. Littlejohn K, Tomlinson K, **Armenian SH**, Nakamura R, Sorrow ML, McCune JS. Feasibility of geriatric assessment before transplant conditioning regimen in older HCT recipients. *Bone Marrow Transplant*. 2021 Mar;56(3):726-729. PMID: 32989242; PMCID: PMC8256689.
129. Chang EK, Chanson D, Teh JB, Iukuridze A, Peng K, Forman SJ, Nakamura R, Wong FL, Cai L, **Armenian SH**. Atrial Fibrillation in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation. *J Clin Oncol*. 2021 Mar 10;39(8):902-910. PubMed PMID: 33417479; PubMed Central PMCID: PMC8078261.
130. Sy A, Chanson D, Berano Teh J, Wong FL, Nakamura R, Dadwal S, **Armenian SH**. Late-occurring infections in a contemporary cohort of hematopoietic cell transplantation survivors. *Cancer Med*. 2021 May;10(9):2956-2966. PMID: 33835722; PMCID: PMC8086032.
131. Tevaarwerk A, Denlinger CS, Sanft T, Ansbaugh SM, **Armenian S**, Baker KS, Broderick G, Day A, Demark-Wahnefried W, Dickinson K, Friedman DL, Ganz P, Goldman M, Henry NL, Hill-Kayser C, Hudson M, Khakpour N, Koura D, McDonough AL, Melisko M, Mooney K, Moore HCF, Moryl N, Moslehi JJ, O'Connor T, Overholser L, Paskett ED, Patel C, Peterson L, Pirl W, Rodriguez MA, Ruddy KJ, Schapira L, Shockney L, Smith S, Syrjala KL, Zee P, McMillian NR, Freedman-Cass DA. Survivorship, Version 1.2021. *J Natl Compr Canc Netw*. 2021 Jun 30;19(6):676-685. PMID: 34214969.
132. Flerlage JE, Hiniker SM, **Armenian S**, Benya EC, Bobbey AJ, Chang V, Cooper S, Coulter DW, Cuglievan B, Hoppe BS, Isenalumhe L, Kelly K, Kersun L, Lambie AJ, Larrier NA, Magee J, Oduro K, Pacheco M, Price AP, Roberts KB, Smith CM, Sohani AR, Trovillion EM, Walling E, Xavier AC, Burns JL, Campbell M.

**Curriculum Vitae**  
**Saro H. Armenian, DO, MPH**

- Pediatric Hodgkin Lymphoma, Version 3.2021. *J Natl Compr Canc Netw*. 2021 Jun 30;19(6):733-754. PMID: 34214968.
133. Ehrhardt J, Flerlage JE, **Armenian SH**, Castellino S, Hodgson DC, Hudson MM. Integration of Hodgkin Treatment and Late Effects Guidelines: Seeing the Forrest Beyond the Trees. *J Natl Compr Canc Netw*. 2021 Jun 30;19(6):755-764. PMID: 34214967.
134. Chow EJ, Doody DR, Di C, **Armenian SH**, Baker KS, Bricker JB, Gopal AK, Hagen AM, Ketterl TG, Lee SJ, Reding KW, Schenk JM, Syrjala KL, Taylor SA, Wang G, Neuhaus ML, Mendoza JA. Pilot randomized controlled trial of mobile health applications to reduce cardiovascular risk factors in hematologic malignancy and hematopoietic cell transplant survivors. *J Cancer Surviv*. 2021 Aug;15(4):554-563. PMID: 33037989.
135. Gangaraju R, Chen Y, Hageman L, Wu J, Francisco L, Kung M, Weisdorf DJ, Forman SJ, Arora M, **Armenian SH**, Bhatia S. Late-occurring Venous Thromboembolism in Allogeneic Blood or Marrow Transplant Survivors - a BMTSS-HiGHS2 Risk Model. *Blood Adv*. 2021 Oct 26;5(20):4102-4111. PMID: 34461633.
136. Berano Teh J, Abdulla F, Peng K, Atencio L, Echevarria M, Iukuridze A, Geller AC, Won FL, Forman SJ, Nakamura R, Modi B, **Armenian SH**. Incidence and Risk Factors for de novo Cutaneous Squamous Cell Carcinoma in a Contemporary Cohort of Long-term Hematopoietic Cell Transplantation Survivors. *J Invest Dermatol*. 2021 Aug;141(8):2073-2076. PMID: 33609555.
137. Bhatia S, Dai C, Landier W, Hageman L, Wu J, Schlichting E, Siler A, Funk E, Bosworth A, Sreng H, Francisco L, Bhatia R, Salzman D, Goldman FD, Forman SJ, Weisdorf DJ, Wong FL, Arora M, **Armenian SH**. Trends in Late Mortality and Life Expectancy after Allogeneic Blood or Marrow Transplantation over Four Decades. *JAMA Oncol*. 2021 Nov 1;7(11):1626-1634. PMID: 34499078.
138. Demissei BG, Hubbard RA, Zhang L, Smith AM, Sheline K, McDonald C, Narayan V, Domchek SM, DeMichele A, Shah P, Clark AS, Fox K, Matro J, Bradbury AR, Knollman H, Getz KD, **Armenian SH**, Januzzi JL, Tang WHW, Liu P, Ky B. Changes in Cardiovascular Biomarkers With Breast Cancer Therapy and Associations With Cardiac Dysfunction. *J Am Heart Assoc*. 2020 Jan 21;9(2):e014708. doi: 10.1161/JAHA.119.014708. Epub 2020 Jan 21. PMID: 31959034; PMCID: PMC7033834.
139. Verbruggen LC, Wang Y, **Armenian SH**, Ehrhardt MJ, van der Pal HJH, van Dalen EC, van As JW, Bardi E, Baust K, Berger C, Castagnola E, Devine KA, Gebauer J, Marchak JG, Glaser AW, Groll AH, Haeusler GM, den Hartogh J, Haupt R, Hjorth L, Kato M, Kepák T, Koopman MMWR, Langer T, Maeda M, Michel G, Muraca M, Nathan PC, van den Oever SR, Pavasovic V, Sato S, Schulte F, Sung L, Tissing W, Uytendroek A, Mulder RL, Kuehni C, Skinner R, Hudson MM, Kremer LCM. Guidance regarding COVID-19 for survivors of childhood, adolescent, and young adult cancer: A statement from the International Late Effects of Childhood Cancer Guideline Harmonization Group. *Pediatr Blood Cancer*. 2020 Dec;67(12):e28702. PMID: 32969160; PMCID: PMC7537044.
140. Ruddy KJ, Patel SR, Higgins AS, **Armenian SH**, Herrmann J. Cardiovascular Health during and after Cancer Therapy. *Cancers (Basel)*. 2020 Dec 11;12(12): 3737. PMID: 33322622; PMCID: PMC7763346.
141. Bhandari R, Teh JB, Herrera C, Echevarria M, Lindenfeld L, Wong FL, Wilson K, **Armenian SH**. Prevalence and risk factors for vitamin D deficiency in long-term childhood cancer survivors. *Pediatr Blood Cancer*. 2021 Jul;68(7):e29048. doi: 10.1002/pbc.29048. Epub 2021 Apr 6. PubMed PMID: 33822476.
142. Giri S, Chen Y, Wu J, Hageman L, Richman J, Francisco L, Landier W, Costa L, McDonald A, Murdaugh D, Wong FL, Weisdorf DJ, Forman SJ, Arora M, **Armenian SH**, Bhatia S. Reduction in Late Mortality Among Patients With Multiple Myeloma Treated With Autologous Peripheral Blood Stem Cell Transplantation-A Blood or Marrow Transplant Survivor Study Report. *Transplant Cell Ther*. 2021 Oct;27(10):840.e1-840.e7. PubMed PMID: 34153501; PubMed Central PMCID: PMC8478837.
143. Aldoss I, Pillai R, Yang D, Yang L, Arslan S, Mokhtari S, Malki MMA, Salhotra A, Shahani S, Ali H, Mei M, Artz A, Snyder D, Afkhami M, **Armenian S**, Stein A, Marcucci G, Forman SJ, Nakamura R, Pullarkat V.

## Curriculum Vitae Saro H. Armenian, DO, MPH

Late and very late relapsed acute lymphoblastic leukemia: clinical and molecular features, and treatment outcomes. *Blood Cancer J.* 2021 Jul 2;11(7):125. doi: 10.1038/s41408-021-00516-1. PubMed PMID: 34215723; PubMed Central PMCID: PMC8253853

144. Chow EJ, Aplenc R, Vrooman LM, Doody DR, Huang YSV, Aggarwal S, **Armenian SH**, Baker KS, Bhatia S, Constine LS, Freyer DR, Kopp LM, Leisenring WM, Asselin BL, Schwartz CL, Lipshultz SE. Late health outcomes after dexrazoxane treatment: a report from the Children's Oncology Group. *Cancer.* Feb 15;128(4):788-796. PMID: 34644414.
145. Landier W, Bhatia S, Wong FL, York JM, Flynn JS, Henneberg HM, Singh P, Smith K, Wasilewski-Masker K, Cherven B, Jasty-Rao R, Leonard M, Connelly JA, **Armenian SH**, Robison LL, Giuliano AR, Hudson MM, Klosky JL. Immunogenicity and Safety of the HPV Vaccine in Young Cancer Survivors: A Phase IIb Single Arm Open-label Noninferiority Trial. *Lancet Child Adolesc Health.* 2022 Jan;6(1):38-48. PMID: 34767765.
146. Wadhwa A, Chen Y, Hageman L, Schlichting E, Funk E, Hicks J, Balas N, Siler A, Wu J, Francisco L, Holmquist A, Orchard P, **Armenian S**, Arora M, Bhatia S. Burden of morbidity after allogeneic blood or marrow transplantation for inborn errors of metabolism – a BMTSS report. *Transplant Cell Ther.* Dec 5;S2666-6367(21)01410-X. doi: 10.1016/j.jtct.2021.11.023. PMID: 34879288; PMCID: PMC8923990.
147. Herrmann J, Lenihan D, **Armenian S**, Barac A, Blaes A, Cardinale D, Carver J, Dent S, Ky B, Lyon AR, López-Fernández T, Fradley MG, Ganatra S, Curigliano G, Mitchell JD, Minotti G, Lang NN, Liu JE, Neilan TG, Nohria A, O'Quinn R, Pusic I, Porter C, Reynolds KL, Ruddy KJ, Thavendiranathan P, Valent P. Defining Cardiovascular Toxicities of Cancer Therapies - An International Cardio-Oncology Society (IC-OS) Consensus Statement. *Eur Heart J.* 2022 Jan 31;43(4):280-299. PMID: 34904661.
148. Wilcox NS, Rotz SJ, Mullen M, Song E, Hamilton BK, Moslehi J, **Armenian SH**, Wu JC, Rhee JW, Ky B. Sex-Specific Cardiovascular Risks of Cancer and Its Therapies. *Circ Res.* 2022 Feb 18;130(4):632-651. PMID: 35175846.
149. Lin C, Baca N, Yun C, **Armenian S**, Freyer DR, Majlessipour F, Mueller L, Kuo DJ, Casillas J, Zabokrtsky K, Ehwerhemuepha L, Torno L. Southern California Pediatric and Adolescent Cancer Survivorship (SC-PACS): Establishing a Multi-Institutional Childhood, Adolescent, and Young Adult Cancer Survivorship Consortium in Southern California. *Cureus.* 2022 Feb 7;14(2):e21981. doi: 10.7759/cureus.21981. eCollection 2022 Feb. PMID: 35282564.
150. Lipshultz ER, Chow EJ, Doody DR, **Armenian SH**, Asselin BL, Baker KS, Bhatia S, Constine LS, Freyer DR, Kopp LM, Schwartz CL, Lipshultz SE, Vrooman LM. Cardiometabolic risk in childhood cancer survivors: a report from the Children's Oncology Group. *Cancer Epidemiol Biomarkers Prev.* 2022 Mar 1;31(3):536-542. PMID: 34810210; PMCID: PMC9067064.
151. Balas N, Hageman L, Wu J, Francisco L, Schlichting E, Bosworth A, Te HS, Wong FL, Landier W, Salzman D, Weisdorf DJ, Forman SJ, Arora M, **Armenian SH**, Bhatia S. Conditioning intensity and probability of live birth after blood or marrow transplantation, a BMTSS report. *Blood Adv.* 2022 Apr 26;6(8):2471-2479. PMID: 34933332; PMCID: PMC9043940.
152. Kindler JM, Guo M, Baker J, McCormack S, **Armenian SH**, Zemel BS, Leonard MB, Mostoufi-Moab S. Persistent musculoskeletal deficits in pediatric, adolescent and young adult survivors of allogeneic hematopoietic stem-cell transplantation. *J Bone Miner Res.* 2022 Apr;37(4):794-803. PMID: 35080067.
153. Pourhassan H, Yang D, Afkhami M, Pillai R, Ball B, Al Malki M, Salhotra A, Ali H, Artz A, Curtin P, **Armenian S**, Stein A, Forman SJ, Marcucci G, Pullarkat V, Nakamura R, Aldoss I. High prevalence and inferior long-term outcomes for TP53 mutations in therapy-related acute lymphoblastic leukemia. *Am J Hematol.* 2022 May;97(5):E171-E173. PubMed PMID: 35132678.
154. Salhotra A, Yang D, Mokhtari S, Hui S, Al-Malki MM, **Armenian S**, Sigala B, Aldoss I, Pullarkat V, Forman SJ, Marcucci G, Nakamura R, Artz A, Wong J, Stein A. Long-Term Follow-up of Patients with Poor-Risk Acute Leukemia Treated on a Phase 2 Trial Undergoing Intensified Conditioning Regimen Prior to



## Curriculum Vitae Saro H. Armenian, DO, MPH

- Allogeneic Hematopoietic Cell Transplantation. *Leuk Lymphoma*. 2022 May;63(5):1220-1226. PMID: 34879769.
155. Bhatia S, Dai C, Landier W, Hageman L, Wu, J, Schlichting E, Siler A, Funk E, Hicks J, Balas N, Bosworth A, Sereng Te H, Francisco L, Bhatia R, Salzman D, Goldman FD, Forman SJ, Weisdorf DJ, Wong FL, **Armenian SH**, Arora M. Trends in Late Mortality and Life Expectancy After Autologous Blood or Marrow Transplantation Over Three Decades: A BMTSS Report. *J Clin Oncol*. 2022 Jun 20;40(18):1991-2003. PMID: 35263165; PMCID: PMC9197350.
156. Mei M, Lee L, Palmer J, Chen R, Tsai NC, Chen L, McBride K, Smith D, Melgar I, Song J, Bonjoc KJ, **Armenian S**, Nwangwu M, Lee P, Zain J, Nikolaenko L, Popplewell L, Nademane A, Chaudhry A, Rosen S, Kwak L, Forman A, Herrera A. Response-adapted anti-PD1 based salvage therapy for Hodgkin lymphoma with nivolumab +/- ICE (NICE). *Blood*. 2022 Jun 23;139(25):3605-3616. PMID: 35316328.
157. Maraldo MV, Levis M, Andreis A, **Armenian S**, Bates J, Brady J, Ghigo A, Lyon AR, Manisty C, Ricardi U, Aznar A, Filippi A. An integrated approach to cardioprotection in lymphomas. *Lancet Haematol*. 2022 Jun;9(6):e445-e454. PMID: 35512725.
158. **Armenian SH**, Chen Y, Hageman L, Wu J, Landier W, Bosworth A, Francisco L, Schlichting E, Bhatia R, Salzman S, Wong FL, Weisdorf DJ, Forman SJ, Arora M, Bhatia S. Burden of Long-term Morbidity borne by Survivors of Acute Myeloid Leukemia (AML) treated with Blood or Marrow Transplantation (BMT) – Results of the BMT Survivor Study (BMTSS). *J Clin Oncol*. 2022 Jun 20;40(18):1991-2003. PMID: 35731989; PMCID: PMC9197350.
159. Ladbury C, Somlo G, Dagens A, Yang D, **Armenian S**, Song JY, Sahebi F, Spielberger R, Popplewell L, Parker P, Forman S, Snyder D, Rincon A, Liu A, Frankel P, Wong J. Long-Term Follow-Up of Multiple Myeloma Patients Treated with Tandem Autologous Transplantation Following Melphalan and Upon Recovery, Total Marrow Irradiation. *Transplant Cell Ther*. 2022 Jul;28(7):367.e1-367.e9. PMID: 35534000.
160. Song M, **Armenian SH**, Bhandari R, Lee K, Ness K, Putt M, Lindenfeld L, Manoukian S, Wade K, Dedio A, Guzman T, Hampton I, Lin K, Baur J, McCormack S, Mostoufi-Moab S. Exercise training and NR supplementation to improve muscle mass and fitness in adolescent and young adult hematopoietic cell transplant survivors: a randomized controlled trial. *BMC Cancer*. 2022 Jul 19;22(1):795. PMID: 35854224.
161. Aziz-Bose R, Margossian R, Ames B, Moss K, Ehrhardt M, **Armenian S**, Yock T, Nekhlyudov L, Williams D, Hudson M, Nohria A, Kenney L. Consensus recommendations for screening and managing childhood cancer survivors at risk for cardiomyopathy: a Delphi study. *JACC:CardioOncol*. 2022 Aug 16;4(3):354-367. PMID: 36213355; PMCID: PMC9537072.
162. Chow EJ, Winestone L, Lupo PJ, Diller LR, Henderson TO, Levine JM, Kadan-Lottick N, Ness KK, Bhatia S, **Armenian SH**. Leveraging clinical trial populations and other data from the Children's Oncology Group for cancer survivorship research. *Cancer Epidemiol Biomarkers Prev*. 2022 Sep 2;31(9):1675-1682. PMID: 35732489; PMCID: PMC9444937.
163. de Baat EC, Mulder RL, **Armenian S**, Feijen EA, Grotenhuis H, Hudson MM, Mavinkurve-Groothuis AM, Kremer LC, van Dalen EC. Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines. *Cochrane Database Syst Rev*. 2022 Sep 27;9:CD014638. PMID: 36162822; PMCID: PMC9512638.
164. Sanft T, Day A, Peterson L, Rodriguez MA, Ansbaugh S, **Armenian S**, Baker KS, Ballinger T, Broderick G, Demark-Wahnefried W, Dickinson K, Fairman NP, Friedman DL, Goldman M, Henry NL, Hill-Kayser C, Hudson M, Khakpour N, Koura D, McDonough AL, Melisko M, Mooney K, Moore HCF, Moryl N, Neuman H, O'Connor T, Overholser L, Paskett ED, Patel C, Pirl W, Porpiglia A, Ruddy KJ, Schapira L, Shockney L, Smith S, Syrjala KL, Tevaarwerk A, Yang EH, Zee P, McMillian NR, Freedman-Cass DA. NCCN Guidelines® Insights: Survivorship, Version 1.2022. *J Natl Compr Canc Netw*. 2022 Oct;20(10):1080-1090. PMID: 36240847.

**Curriculum Vitae**  
**Saro H. Armenian, DO, MPH**

165. Bhandari R, Berano Teh J, He T, Peng K, Iukuridze A, Atencio L, Nakamura R, Mostoufi-Moab S, McCormack, Lee K, Wong FL, **Armenian SH**. Association between body composition and development of glucose intolerance after allogeneic hematopoietic cell transplantation. *Cancer Epidemiol Biomarkers Prev*. 2022 Nov 2;31(11):2004-2010. PMID: 35797113.
166. Bhandari R, Berano Teh J, He T, Nakamura R, Artz AS, Jankowska MM, Forman SJ, Wong FL, **Armenian SH**. Social vulnerability and risk of non-relapse mortality after allogeneic hematopoietic cell transplantation. *J Natl Cancer Inst*. 2022 Nov 14;114(11):1484-1491. PMID: 35980163; PMCID: PMC9664181.
167. Ware M, Kadan-Lottick N, Devidas M, Terrell S, Chow E, Ehrhardt MJ, Hardy K, Chemaitilly W, Hein W, Winick N, Teachey D, Esbenschade A, **Armenian S**, Partin R, Ness KK. Design and Methods of a Randomized Web-based Physical Activity Intervention among Children with Cancer: A Report from the Children's Oncology Group. *Contemp Clin Trials*. 2022 Nov;122:106961. PMID: 36228982. PMCID: PMC9669240.
168. van den Oever SR, Pluijm SMF, Skinner R, Glaser A, Mulder RL, **Armenian S**, Bardi E, Berger C, Ehrhardt MJ, Winther JF, Marchak JG, Haeusler GM, den Hartog J, Hjorth L, Kepak T, Kriviene I, Langer T, Maeda M, Márquez-Vega C, Michel G, Muraca M, Najib M, Nathan PC, Panasiuk A, Prasad M, Roganovic J, Uyttebroeck A, Winther JF, Zaletel LZ, van Dalen EC, van der Pal H, Hudson MM, Kremer LCM on behalf of the IGHC COVID-19 working group. Childhood Cancer Survivorship Care during the COVID-19 pandemic: An International Report of Practice Implications and Provider Concerns. *J Cancer Surv*. 2022 Dec;16(6):1390-1400 PMID: 35020136; PMCID: PMC8753338.
169. de Baat EC, van Dalen EC, Mulder RL, Hudson MM, Ehrhardt MJ, Engels FK, Feijen EAM, Grotenhuis HB, Leerink JM, Kapusta L, Kaspers GJL, Merckx R, Mertens L, Skinner R, Tissing WJE, de Vathaire F, Nathan PC, Kremer LCM, Mavinkurve-Groothuis AMC\*, **Armenian SH\***. Primary cardioprotection with dexrazoxane in childhood cancer patients expected to receive anthracyclines: recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group. *Lancet Child Adolesc Health*. 2022 Dec;6(12):885-894. PMID: 36174614.
170. Ladbury C, **Armenian S**, Bosworth A, He T, Wong FL, Dandapani S, Han C, Liu A, Al Malki M, Rosenthal J, Stein A, Wong J. Risk of Subsequent Malignant Neoplasms Following Hematopoietic Stem Cell Transplantation with Total Body Irradiation or Total Marrow Irradiation: Insights from Early Follow-Up. *Transplant Cell Ther*. 2022 Dec;28(12):860.e1-860.e6. PMID: 36167306.
171. Wolfson J, Bhatia S, Hageman L, Schlichting E, Balas N, Bosworth A, Sreng Te H, Francisco L, Funk E, Hicks J, Landier W, Wu J, Siler A, **Armenian S**, Arora M, Aswani M. Neighborhood Disadvantage, Health Status and Healthcare Utilization after Blood or Marrow Transplantation – BMTSS Report. *Blood Adv*. 2023 Feb 14;7(3):293-301. PMID: 35834730.
172. Barth M, Xavier AC, **Armenian S**, Audino AN, Blazin L, Bloom D, Chung J, Davies K, Ding H, Ford JB, Galardy PJ, Hanna R, Hayashi R, Lee-Miller C, Machnitz AJ, Maloney KW, Marks L, Martin PL, McCall D, Pacheco M, Reilly AF, Roshal M, Song S, Weinstein J, Zarnegar-Lumley S, McMillian N, Schonfeld R, Sundar H. Pediatric Aggressive Mature B-Cell Lymphomas, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw*. 2022 Nov;20(11):1267-1275. PMID: 36351334.
173. Narayan H, Sheline K, Wong V, Kuo D, Choo S, Yoon J, Leger K, Kutty S, Fradley M, Tremoulet A, Ky B, **Armenian S**, Guha A. Cardiovascular toxicities with pediatric tyrosine kinase inhibitor therapy: an analysis of events reported to the Food and Drug Administration. *Pediatr Blood Cancer*. 2023 Feb;70(2):e30059. doi: 10.1002/pbc.30059. PMID: 36385736.
174. Herrera AF, Chen L, Nieto Y, Holmberg L, Johnson P, Mei M, Popplewell L, **Armenian S**, Cao T, Farol L, Sahebi F, Spielberger R, Chen R, Nademanee A, Puvarel S, Nwagwu M, Lee P, Song J, Skarbnik A, Kennedy N, Peters L, Rosen S, Kwak L, Forman S, Feldman T. Nivolumab and Brentuximab Vedotin After Autologous Stem Cell Transplantation for High-Risk Classic Hodgkin Lymphoma: a Multicentre, Phase 2 Trial. *Lancet Haematol*. 2023 Jan;10(1):e14-e23. PMID: 36403579.

**Curriculum Vitae**  
**Saro H. Armenian, DO, MPH**

175. Sanchez-Luge S, Landier W, Dai C, Hageman L, Ross E, Balas N, Bosworth A, Te HS, Wu J, Francisco L, Wong FL, Forman SJ, **Armenian SH**, Weisdorf DJ, Bhatia S. Potentially Inappropriate Medications in geriatric blood or marrow transplantation (BMT) survivors: A BMT Survivor Study report. *Cancer*. 2023 Feb 1;129(3):473-482. PMID: 36413424.
176. Bhatia S, Dai C, Hageman L, Wu J, Schlichting E, Siler A, Funk E, Hicks J, Lim S, Balas N, Bosworth A, Te HS, Francisco L, Bhatia R, Forman SJ, Wong FL, Arora M, **Armenian SH**, Weisdorf DJ, Landier W. Financial Burden in Blood or Marrow Transplantation Survivors During the COVID-19 Pandemic: A BMTSS Report. *J Clin Oncol*. 2023 Feb 10;41(5):1011-1022.
177. Holmqvist AS, Chen Y, Hageman L, Landier L, Wu J, Francisco LF, Schlichting Ross E, Balas N, Goldman F, Rosenthal J, Wong FL, Weisdorf D, **Armenian SH**, Bhatia S. Severe, life-threatening and fatal chronic health conditions after allogeneic blood or marrow transplantation in childhood. *Cancer*. 2023 Feb 15;129(4):624-633. PMID: 36484292.
178. Yang E, Dornisch A, Nerb L, Helsten T, Kaiser BN, Arstizabal P, **Armenian S**, Torno LL, Baca NM, Genensen MC, Su I, Romero SAD. A Multi-Component Telehealth Intervention to Improve Oncofertility Care Delivery among Young Cancer Patients: A Pilot Study. *J Adolesc Young Adult Oncol*. 2022 May 27; doi: 10.1089/jayao.2021.0224. [Epub ahead of print] PubMed PMID: 35639102.
179. Wang X, Singh P, Zhou L, Sharafeldin N, Landier W, Hageman L, BurrIDGE P, Yasui Y, Sapkota Y, Blanco JG, Morton L, Oeffinger K, Hudson MM, Chow EJ, **Armenian SH**, Neglia JP, Ritchey AK, Hawkins DS, Ginsberg JP, Robison LL, Armstrong GT, Bhatia S. Genomewide association study identifies *ROBO2* as a novel susceptibility gene for anthracycline-related cardiomyopathy in childhood cancer survivors. *J Clin Oncol*. 2022 Dec 12;JCO2201527. doi: 10.1200/JCO.22.01527. Online ahead of print. PMID: 36508697.
180. McDonald A, Dai C, Meng Q, Hageman L, Richman J, Wu J, Francisco L, Ross E, Balas N, Bosworth A, Te HS, Wong FL, Landier W, Salzman D, Bhatia R, Weisdorf DJ, Forman SJ, Arora M, **Armenian SH**, Bhatia S. Malignant Neoplasms of the Gastrointestinal Tract After Blood or Marrow Transplant. *JAMA Oncol*. 2023 Jan 19. doi: 10.1001/jamaoncol.2022.6569. Online ahead of print. PMID: 36656600.
181. Chow EJ, Aggarwal S, Doody DR, Aplenc R, **Armenian SH**, Baker KS, Bhatia S, Blythe N, Colan SD, Constine LS, Freyer DR, Kopp LM, Laverdière C, Leisenring WM, Sasaki N, Vrooman LM, Asselin BL, Schwartz CL, Lipshultz SE. Dexrazoxane and heart function in long-term survivors of childhood cancer. *J Clin Oncol*. 2023 Jan 20;JCO2202423. doi: 10.1200/JCO.22.02423. Online ahead of print. PMID: 36669148
182. Weil BR, Murphy AJ, Liu Q, Howell RM, Smith SA, Weldon CB, Mullen EA, Madenci AL, Leisenring WM, Neglia JP, Turcotte LM, Oeffinger KC, Termuhlen AM, Mostoufi-Moab S, Levine JM, Krull KR, Yasui Y, Robison LL, Armstrong GT, Chow EJ, **Armenian SH**. Late health outcomes among survivors of Wilms tumor diagnosed over three decades: a report from the Childhood Cancer Survivor Study. *J Clin Oncol*. 2023 Jan 24;JCO2202111. doi: 10.1200/JCO.22.02111. Online ahead of print. PMID: 36693221.
183. Chan A, Ports K, Ng DQ, Nasr R, Hsu S, Armenian S, Baca N, Freyer DR, Kuo DJ, Lin C, Milam J, Valerin J, Yun C, Torno L. Unmet Needs, Barriers, and Facilitators for Conducting Adolescent and Young Adult Cancer Survivorship Research in Southern California: A Delphi Survey. *J Adolesc Young Adult Oncol*. 2023 Jan 25. doi: 10.1089/jayao.2022.0086. Online ahead of print. PMID: 36695742.
184. Johnston EE, Meng GQ, Hageman L, Wu J, Ross E, Lim S, Balas N, Bosworth A, Te HS, Francisco L, Bhatia R, Forman SJ, Wong FL, **Armenian SH**, Weisdorf DJ, Landier W, Bhatia S. Risk of COVID-19 infection in long-term survivors of blood or marrow transplantation: a BMTSS report. *Blood Adv*. 2023 Feb 1;bloodadvances.2022009550. Online ahead of print. PMID: 36724527.
185. Aziz-Rose R, **Armenian SH**, Nohria A, Kenney LB. Reply: Novel technologies must be considered for childhood cancer survivors at risk for cardiomyopathy. *JACC CardioOncol*. 2023 Feb 21;5(1):157. doi: 10.1016/j.jacc.2022.12.004. eCollection 2023 Feb. PMID: 36875896.

**Curriculum Vitae**  
**Saro H. Armenian, DO, MPH**

186. Hayek S, Libresco G, Barda N, Chao C, Xu L, Cannavale KL, Izraeli S, **Armenian SH**. Chronic health conditions among long-term survivors of adolescent and young adult (AYA) cancer: a comparison of outcomes in Israel and the U.S. *Cancer*. 2023 Mar 17. doi: 10.1002/cncr.34740. Online ahead of print. PMID: 36929478.
187. Lee K, Lindenfeld L, Echevarria M, Hsu JA, Wong FL, Narayan H, Lau C, Cai, LY, Pal SK, **Armenian SH\***, Rhee JW\*. Cardiovascular profile of contemporary treatments of renal cell carcinoma: a single-center prospective study. *Int J Cardiol*. 2023 Mar 21:S0167-5273(23)00451-5. Online ahead of print. PMID: 36958393.
188. Singh P, Crossman DK, Zhou L, Wang X, Sharafeldin N, Hageman L, Blanco JG, Burrige P, **Armenian SH**, Balis F, Cole C, Hawkins D, Keller F, Hudson MM, Neglia JP, Ritchey AK, Winnick N, Landier W, Bhatia S. Haptoglobin Gene Expression and Anthracycline-related Cardiomyopathy in Childhood Cancer Survivors - a COG-ALTE03N1 Report. In Press, *JACC CardioOncol*.
189. Gangaraju R, Chen Y, Hageman L, Landier W, Balas N, Ross E, Francisco L, Bosworth A, Te HS, Wong FL, Weisdorf DJ, Bhatia R, Forman SJ, **Armenian SH**, Bhatia S. Prediction of coronary heart disease in blood or marrow transplantation recipients. In Press, *JACC CardioOncol*.
190. Bates JE, Rancati T, Keshavarz H, Gagliardi G, Aznar MC, Howell RM, Shrestha S, Moiseenko V, Yorke E, **Armenian S**, Kremer L, Chen MH, van der Pal H, Cutter D, Constine LS, Hodgson D. Cardiac disease in childhood cancer survivors treated with radiotherapy: a PENTEC comprehensive review. In Press, *Int J Radiat Oncol Biol Phys*.
191. Lee K, Iukuridze A, He T, Bosworth A, Lindenfeld L, The JB, Echevarria M, Albanese S, Atencio L, Bhandari R, Wong FL, Artz AS, Siddiqi T, Nikolaenko L, Zain J, Mei M, Shouse G, Popplewell LL, Herrera AF, Budde E, Forman SJ, **Armenian SH**. Association Between Pretreatment Skeletal Muscle and Outcomes After CAR T-Cell Therapy. In Press, *J Natl Compr Canc Netw*.
192. Ehrhardt MJ\*, Leerink JM\*, Mulder RL, Mavinkurve-Groothuis A, Kok W, Nohria A, Nathan PC, Merckx R, de Baat E, Asogwa OA, Skinner R, Wallace H, Feijen EAM, de Ville de Goyet M, Prasad M, Bardi E, Pavasovic V, van der Pal H, Fresneau B, Demoor-Goldsmith C, Hennewig U, Steinberger J, Grotenhuis H, Plummer C, Chen MH, Teske AJ, Haddy N, van Dalen EC, Constine LS, Chow EJ, Levitt G, Hudson MM, Kremer LC\*, **Armenian SH\***. Updated Cardiomyopathy Surveillance Recommendations for Survivors of Childhood, Adolescent, and Young Adult Cancer from the International Late Effects of Childhood Cancer Guideline Harmonization Group. In Press, *Lancet Oncol*.

*\*Contributed equally*

**Manuscripts submitted for peer review**

1. Lee K, Shamunee J, Lindenfeld L, Ross E, Hageman E, Sedrak MS, Wong FL, Nakamura R, Forman S, Bhatia S, **Armenian SH**. Feasibility of Implementing a Supervised Telehealth Exercise Intervention in Frail Survivors of Hematopoietic Cell Transplantation.
2. Murdaugh D, Sharafeldin N, Hageman L, Wu J, Bosworth A, Landier W, Weisdorf D, Forman SJ, **Armenian S**, Arora M, Bhatia S. Association between endorsement of memory problems and health outcomes after blood or marrow transplantation: a blood or marrow transplantation survivor study report.
3. Cannavale KL, Xu L, Nau CL, **Armenian SH**, Bhatia S, Wong FL, Huang PYS, Cooper R, Chao C. Neighborhood factors associated with late effect among survivors of adolescent and young adult cancer.
4. Sharafeldin N, Zhou L, Singh P, Crossman DK, Wang X, Hageman L, Landier W, Blanco JG, Burrige P, Sapkota Y, Yasui Y, Armstrong GT, Robison LL, Hudson MM, Oeffinger K, Chow EJ, **Armenian SH**, Weisdorf DJ, Bhatia S. A gene-level analysis identifies novel genetic associations with anthracycline-induced cardiomyopathy in cancer survivors.
5. Wang X, Richman J, Singh P, Zhou L, Sharafeldin N, Landier W, Hageman L, Yasui Y, Blanco JG, Sapkota Y, Armstrong GT, Oeffinger KC, Hudson MM, Chow EJ, **Armenian SH**, Robison LL, Bhatia S. Use of

## Curriculum Vitae Saro H. Armenian, DO, MPH

Clinical and genetic markers to classify anthracycline-exposed cancer survivors by individual cardiomyopathy risk – a report from the Children’s Oncology Group ALTE03N1 study and the Childhood Cancer Survivor Study.

6. Kumar A, Duault C, Khani AT, Ortiz AS, Lee SJ, Chan A, McDonald T, Huang M, Lacayo NJ, Sakamoto KM, Yu J, Caligiuri M, Hurtz C, Carroll M, Tasian S, Ghoda L, Marcucci G, Gu Z, Rosen ST, **Armenian S**, Izraeli S, Chen CW, Forman SJ, Maecker H, Swaminathan S. Countering the intrinsic suppression of type I interferon production in B-cell acute lymphoblastic leukemia using IL-15-producing natural killer cells.
7. McCune JS, **Armenian SH**, Nakamura R, Shan H, Kanakry CG, Mohanan E, Mielcarek M, Mager DE. Immunosuppressant adherence in adult outpatient hematopoietic cell transplant recipients.
8. Singh P, Shah DA, Jouni M, Crossman DK, Magdy T, Qiu S, Wang X, Zhou L, Sharafeldin N, Hageman L, Blanco JG, **Armenian SH**, Balis F, Hawkins DS, Keller F, Hudson MM, Neglia JP, Ritchey AK, Ginsberg JP, Landier W, Bhatia R, Burrige P, Bhatia S. Differentially Expressed Genes and Anthracycline-induced Cardiomyopathy in Childhood Cancer Survivors – a COG-ALTE03N1 Report.
9. Nakamura R, Patel B, Kim S, Wong FL, **Armenian SH**, Groarke EM, Kessler DA, Hebert KM, Heim M, Eapen M, Young NS. Conditional survival and standardized mortality ratios of patients with severe aplastic anemia surviving at least one year after hematopoietic cell transplantation or immunosuppressive therapy.
10. Singh P, Zhou L, Shah DA, Cejas RB, Crossman DK, Jouni M, Magdy T, Lu AT, Sharafeldin N, Hageman L, Horvath S, **Armenian SH**, Balis F, Hawkins DS, Keller FG, Hudson MM, Neglia JP, Ritchey AK, Ginsberg JP, Landier W, Burrige P, Bhatia S. Identification of novel hyper- or hypo-methylated CpG sites and genes associated with anthracycline-induced cardiomyopathy – a COG-ALTE03N1 study.
11. Balas N, Richman J, Landier W, Shrestha S, Bruxvoort KJ, Hageman L, Meng Q, Ross E, Bosworth A, Te HK, Wong FL, Bhatia R, Forman SJ, Armenian SH, Weisdorf DJ, Bhatia S. Risky Health Behaviors and Subsequent Mortality after Blood or Marrow Transplantation: a BMTSS report.
12. Godfrey J, Mei M, Chen L, Budde E, **Armenian S**, Puvarel S, Nikolaenko L, Chen R, Daniels S, Kennedy N, Peters L, Rosen ST, Forman SJ, Popplewell LL, Kwak LW, Herrera AF. Results from a phase I trial of pembrolizumab plus vorinostat in relapsed/refractory B-cell non-Hodgkin lymphoma.
13. Oliver MM, Meng Q, Hageman L, Landier W, Balas N, Ross E, Francisco L, Bosworth A, Te HS, Wong FL, Bhatia R, Forman SJ, **Armenian SH**, Weisdorf DJ, Bhatia S. Healthcare Utilization by Long-Term Survivors of Blood or Marrow Transplantation – a BMT Survivor Study Report.
14. Wang X, Singh P, Zhou L, Sharafeldin N, Cejas RB, Landier W, Hageman L, Burrige P, Yasui Y, Sapkota Y, Oeffinger KC, Hudson MM, Chow EJ, **Armenian SH**, Neglia JP, Ritchey AK, Hawkins DS, Ginsberg JP, Robison LL, Armstrong GT, Bhatia S. DNA Damage Response and Repair Genes and Anthracycline-induced Cardiomyopathy in Childhood Cancer Survivors.
15. Giri S, Harmon C, Landier W, Chen Y, Wu J, Hageman L, Balas N, Francisco L, Bosworth A, Weisdorf DJ, Forman SJ, **Armenian SH**, Williams G, Bhatia S. Association between pre-transplant body composition and new onset chronic health conditions among adults with lymphoma treated with autologous peripheral blood stem cell transplantation – a BMTSS Report.
16. Otth M, Kasteler R, Mulder RL, Agrusa JE, **Armenian SH**, Barnea D, Berger C, Bergeron-Lafaurie A, Bhatt NS, Bourke SJ, Catagnola E, Constine L, Demoor-Goldschmidt C, Goutaki M, Green DM, Hennewig U, Hudouin V, Hudson MM, Kremer LC, Latzin P, Ng A, Oeffinger K, Ronckers C, Schindera C, Skinner R, Sommer G, Srinivasan S, Stokes DS, Versluys B, Waespe N, Weiner DJ, Dietz AC, Kuehni CE. Recommendations for surveillance of pulmonary dysfunction in childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group.
17. Mei M, Chen L, Godfrey J, Song J, Egelston C, Budde LE, **Armenian S**, Nikolaenko L, Nwangwu M, Guo W, Gao L, Lee P, Chen R, Daniels S, Kennedy N, Peters L, Rosen ST, Forman SJ, Popplewell LL, Kwak

## Curriculum Vitae Saro H. Armenian, DO, MPH

LW, Herrera AF. Pembrolizumab plus vorinostat induces responses in patients with Hodgkin lymphoma who are refractory to prior PD-1 blockade.

18. Rhee JW, Pillai R, He T, Bosworth A, Chen S, Atencio L, Oganesyan A, Peng K, Guzman T, Lukas K, Sigala B, Iukuridze A, Lindenfeld L, Jamal F, Natarajan P, Goldsmith S, Krishnan A, Rosenzweig M, Wong FL, Forman SJ, **Armenian SH**. Clonal hematopoiesis and cardiovascular disease in patients with multiple myeloma undergoing hematopoietic cell transplantation.

### Abstracts

1. **Armenian SH**, Chutuape MA, Stitzer ML. Risk factors for discharges against medical advice from a short-term hospital detoxification unit. College on Problems of Drug Dependence, 1998.
2. **Armenian SH**, Singh J, Arrieta AC. Bacteremia and patient mortality in a pediatric intensive care unit. European Congress of Chemotherapy and Infection, 2002.
3. **Armenian SH**, La Via WV, Siegel SE, Mascarenhas L. Evaluation of persistent pulmonary infiltrates in pediatric oncology patients. International Society of Pediatric Oncology, 2005.
4. \***Armenian SH**, Sun CL, Francisco L, Steinberger J, Kurian S, Wong L, Sharp J, Sposto R, Forman SJ, Bhatia S. Late congestive heart failure (CHF) following hematopoietic cell transplantation (HCT). American Society of Clinical Oncology, 2007.
5. \***Armenian SH**, Nash KA, Kapoor N, Franklin J, Gaynon PS, Ross LA, Hoffman JA. The use of galactomannan and polymerase chain reaction in blood for the early diagnosis of invasive aspergillus in a high-risk pediatric population. 3rd Advances Against Aspergillosis, 2008.
6. \***Armenian SH**, Sun CL, Francisco L, Baker KS, Forman SJ, Bhatia S. Differential morbidity by ethnicity in long-term survivors of hematopoietic cell transplantation (HCT): a report from the bone marrow transplant survivor study (BMTSS). American Society of Hematology, 2008.
7. Patel R, Kurian S, Sun CL, Francisco L, Wong FL, Sharp J, **Armenian SH**, Forman SJ, Bhatia S. Challenges for retrospective cohort studies: A profile of patients who refuse participation or are lost-to follow-up. American Society of Clinical Oncology, 2009.
8. **Armenian S**, Patel R, Kurian S, Sun CL, Francisco L, Wong L, Sharp J, Forman S, Bhatia S. Challenges for retrospective cohort studies: A profile of patients who refuse participation or are lost-to follow-up. Beckman Research Institute, City of Hope, Annual Poster Presentation, 2009.
9. Landier W, Sun CL, Arewasikporn A, **Armenian SH**, Francisco L, Kurian S, Wilson K, Bhatia S. Impact of care at a long-term follow-up (LTFU) clinic on the acquisition of knowledge regarding treatment-related health risks by childhood cancer survivors. European Symposium on Late Complications after Childhood Cancer 2009.
10. **Armenian SH**, Sun CL, Mills G, Berano Teh J, Francisco L, Wong FL, Forman SJ, Bhatia S. Late cardiovascular complications in survivors of hematopoietic cell transplantation (HCT). American Society of Hematology, 2009.
11. \***Armenian SH**, Sun CL, Francisco L, Arora M, Baker KS, Forman SJ, Smita Bhatia S. Health behaviors and cancer screening practices in long-term survivors of hematopoietic cell transplantation (HCT): a report from the Bone Marrow Transplant Survivor Study (BMTSS). Bone Marrow Transplantation Tandem Meetings, 2010.
12. **Armenian SH**, Sun CL, Mills G, Shannon T, Francisco L, Wong FL, Forman SJ, Bhatia S. Predictors of therapy-related congestive heart failure (CHF) following hematopoietic cell transplantation (HCT). American College of Cardiology, 2010.
13. \***Armenian SH**, Landier W, Sun CL, Lee J, Zomorodi M, Francisco L, Wilson K, Bhatia S. Yield of screening for cardiac dysfunction and cardiovascular risk factors in childhood cancer survivors using the Children's

## Curriculum Vitae

### Saro H. Armenian, DO, MPH

- Oncology Group (COG) long-term follow-up (LTFU) guidelines: City of Hope experience. International Conference on Long Term Complications of Treatment of Children and Adolescents for Cancer, 2010.
14. Landier W, Francisco L, Wilson K, **Armenian SH**, Phang S, Bhatia S. Development of a computerized clinic management system to facilitate standardized follow-up of childhood cancer survivors. International Conference on Long Term Complications of Treatment of Children and Adolescents for Cancer, 2010.
  15. Wilson K, Landier W, Zomorodi M, Herrera C, Francisco L, **Armenian S**, Bhatia S. Use of the Children's Oncology Group (COG) Long-Term Follow-up (LTFU) Guidelines to facilitate appropriate counseling of asplenic childhood cancer survivors. International Conference on Long Term Complications of Treatment of Children and Adolescents for Cancer, 2010.
  16. **Armenian SH**, Landier W, Sun CL, Lee J, Zomorodi M, Francisco L, Wilson K, Bhatia S. Screening for cardiac dysfunction and cardiovascular risk factors in childhood cancer survivors using the Children's Oncology Group (COG) long-term follow-up (LTFU) guidelines. American Society of Clinical Oncology, 2010.
  17. Mascarenhas L, **Armenian SH**, Harrington JL, Mahmoud H, Sposto H, Malogolowkin MH. Phase I trial of oxaliplatin and doxorubicin in children and adolescents with recurrent solid tumors. American Society of Clinical Oncology, 2010.
  18. \*VanderWalde AM, Sun CL, Francisco L, **Armenian SH**, Teh J, Wong FL, Kogut N, Krishnan A, Nademanee A, Popplewell L, Stein A, Forman SJ, Bhatia S. Cause-specific Conditional Survival in 2603 Consecutive Patients undergoing Autologous Hematopoietic Cell Transplantation (aHCT) over a 20-year period. American Society of Hematology, 2010.
  19. \*Laddaran L, Sun CL, VanderWalde A, Francisco L, **Armenian SH**, Teh J, Wong FL, Karanes C, Kogut N, Krishnan A, Nademanee A, O'Donnell M, Parker P, Popplewell L, Stein A, Forman SJ, Bhatia S. Early mortality after hematopoietic cell transplantation (HCT) for hematologic malignancies. American Society of Hematology, 2010.
  20. \***Armenian SH**, Sun CL, Kawashima T, Arora M, Leisenring W, Sklar CA, Baker KS, Francisco L, The JB, Mills G, Wong FL, Rosenthal J, Diller L, Hudson MM, Oeffinger KC, Robison LL, Bhatia S. Long-term outcomes in survivors of childhood cancer treated with hematopoietic cell transplantation (HCT) versus conventional therapy: a report from the Bone Marrow Transplant Survivor Study (BMTSS) and Childhood Cancer Survivor Study (CCSS). American Society of Hematology, 2010.
  21. \***Armenian SH**, Ding Y, Mills G, Sun CL, Wong FL, Wang S, O'Connor T, Forman S, Bhatia S. Genetic susceptibility to anthracycline-related congestive heart failure (A-CHF) in survivors of hematopoietic cell transplantation (HCT). Bone Marrow Transplantation Tandem Meetings, 2011.
  22. Sun CL, Teh JB, Tomassian L, Gyorffey J, Wang S, Popplewell L, Krishnan A, Nademanee A, Forman SJ, **Armenian SH**, Ravi R, Bhatia S. Predictors of therapy-related myelodysplasia and acute myeloid leukemia (t-MDS/AML) after autologous hematopoietic cell transplantation (aHCT) for hematologic malignancies. Bone Marrow Transplantation Tandem Meetings, 2011.
  23. **Armenian SH**, Sun CL, Mills G, Shannon T, Francisco L, Wong FL, Forman SJ, Bhatia S. Incidence and predictors of congestive heart failure (CHF) after hematologic malignancies treated with autologous hematopoietic cell transplantation (aHCT). American Society of Clinical Oncology, 2011.
  24. Wong FL, Bhatia S, Kurian S, Landier W, Francisco L, Leisenring W, Hudson M, Armstrong GT, Mertens A, Stovall M, Yasui Y, Robison LL, Lipshultz SE, **Armenian SH**. Evaluation of the effectiveness of the Children's Oncology Group (COG) Long-term Follow-up Guidelines in reducing the risk of anthracycline-related congestive heart failure (CHF) in long-term survivors of childhood cancer. European Symposium on Late Complications after Childhood Cancer, 2011.
  25. Landier W, Lee J, Thomas O, Wong FL, **Armenian SH**, Francisco L, Herrera C, Kasper C, Wilson K, Zomorodi M, Bhatia S. Yield and Utility of Screening for Late-Effects using the Children's Oncology Group

## Curriculum Vitae Saro H. Armenian, DO, MPH

Long-Term Follow-Up (COG-LTFU) Guidelines. European Symposium on Late Complications after Childhood Cancer, 2011.

26. \*Sun CL, Kersey J, Francisco L, **Armenian SH**, Baker KS, Weisdorf DJ, Forman SJ, Bhatia S. Burden of morbidity in 10+ year survivors of hematopoietic cell transplantation (HCT): A Report from the Bone Marrow Transplant Survivor Study (BMTSS). American Society of Hematology, 2011.
27. \***Armenian SH**, Sun CL, Shannon T, Blum E, Francisco L, Venkatraman K, Samoa R, Wong FL, Forman SJ, Bhatia S. Cardiovascular risk factors in hematopoietic cell transplantation (HCT) survivors: role in development of subsequent cardiovascular disease. American Society of Hematology, 2011.
28. \*Wong FL, Bhatia S, Kurian S, Landier W, Francisco L, Leisenring W, Hudson M, Armstrong GT, Mertens A, Stovall M, Yasui Y, Robison LL, Lipshultz SE, **Armenian SH**. Cost-effectiveness of the Children's Oncology Group (COG) long-term follow-up (LTFU) guidelines in reducing the risk of congestive heart failure (CHF) in long-term childhood cancer survivors. International Conference on Long Term Complications of Treatment of Children and Adolescents for Cancer, 2012.
29. \*Wong FL, Bhatia S, Kurian S, Landier W, Francisco L, Leisenring W, Hudson M, Armstrong GT, Mertens A, Stovall M, Yasui Y, Robison LL, Lipshultz SE, **Armenian SH**. Efficacy of the Children's Oncology Group (COG) long-term follow-up guidelines in reducing risk of congestive heart failure in childhood cancer survivors. American Society of Clinical Oncology, 2012.
30. \***Armenian SH**, Sun CL, Vase T, Mills G, Atencio L, Francisco L, Palmer J, VanderWalde A, Wong FL, Rosenthal J, Kogut NM, Popplewell L, Snyder DS, Stein AS, O'Donnell M, Forman SJ, Bhatia S. Conditional Survival and Cause-Specific Mortality in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Hematologic Malignancy Over Three Decades. American Society of Hematology, 2012.
31. \***Armenian SH**, Ding Y, Mills G, Sun CL, Venkatraman K, Wong FL, Senitzer D, Wang S, Forman SJ, Bhatia S. Genetic Susceptibility to Anthracycline-Related Congestive Heart Failure in Survivors of Hematopoietic Cell Transplantation. American Society of Hematology, 2012.
32. \*Berano Teh J, Sun CL, Wilczynski C, Epstein J, Spielberger R, Maghami E, Landier W, Francisco L, **Armenian SH**, Wong FL, Forman SJ, Bhatia S. Human Papilloma Virus (HPV)-attributable Subsequent Malignant Neoplasms (SMNs) after Hematopoietic Cell Transplantation (HCT) – a potentially preventable outcome. American Society of Hematology, 2012.
33. **Armenian SH**, Sun CL, Blum E, Vase T, Kang M, Wong FL, Forman SJ, Bhatia S. Incidence and predictors of late-occurring cirrhosis in long-term survivors of allogeneic hematopoietic cell transplantation (HCT). Bone Marrow Transplantation Tandem Meetings, 2013.
34. **Armenian SH**, Gelehrter SK, Vase T, Venkatramani R, Landier W, Wilson KD, Herrera C, Reichman L, Menteeer JD, Mascarenhas L, Freyer DR, Venkataraman K, Bhatia S. Comprehensive profiling of cardiac dysfunction in asymptomatic childhood cancer survivors (CCS) treated with anthracyclines. American Society of Clinical Oncology, 2013.
35. \*Sun CL, Wang X, Liu W, **Armenian SH**, Hankonarson H, Hageman L, Ding Y, Landier W, Keller FG, Neglia JP, Desai SJ, Sklar CA, Castellino SM, Cherrick I, Dreyer Z, Yasui Y, Relling MV, Bhatia S. Hyaluronidase synthase 3 (HAS3) variant and anthracycline-related cardiomyopathy – a report from the Children's oncology group. American Society of Clinical Oncology, 2013.
36. \***Armenian SH**, Gelehrter SK, Vase T, Venkatramani R, Landier W, Wilson KD, Herrera C, Reichman L, Menteeer JD, Mascarenhas L, Freyer DR, Venkataraman K, Bhatia S. Comprehensive profiling of cardiac dysfunction in asymptomatic childhood cancer survivors (CCS) treated with anthracyclines. International Conference on Long Term Complications of Treatment of Children and Adolescents for Cancer, 2013.
37. \*Kremer CM, Mulder RL, Oeffinger KC, Bhatia S, Landier W, Levitt G, Constone LS, Wallace WH, Caron HN, **Armenian SH**, Skinner R, Hudson MM. International Late Effects of Childhood Cancer Guideline



## Curriculum Vitae Saro H. Armenian, DO, MPH

- Harmonization Group. International Conference on Long Term Complications of Treatment of Children and Adolescents for Cancer, 2013.
38. \*Sun CL, Wang X, Liu W, **Armenian SH**, Hankonarson H, Hageman L, Ding Y, Landier W, Keller FG, Neglia JP, Desai SJ, Sklar CA, Castellino SM, Cherrick I, Dreyer Z, Yasui Y, Relling MV, Bhatia S. Hyaluronidase synthase 3 (HAS3) variant and anthracycline-related cardiomyopathy – a report from the Children’s oncology group. International Conference on Long Term Complications of Treatment of Children and Adolescents for Cancer, 2013.
  39. \***Armenian SH**, Sun CL, Arora M, Baker KS, Francisco L, Rosenthal J, Weisdorf D, Forman SJ, Bhatia S. Long-term health-related outcomes in survivors of childhood hematopoietic cell transplantation (HCT): a report from the Bone Marrow Transplant Survivor Study (BMTSS). American Society of Hematology, 2013.
  40. Chow EJ, Asselin BL, Schwartz CL, Doody DR, Leisenring WM, Aggarwal S, Baker KS, Bhatia S, Chen L, Constine LS, Freyer DR, Leonard MS, Lipshultz SE, **Armenian SH**. Late mortality after dexrazoxane (DRZ) treatment: an update from the Children’s Oncology Group (COG). American Society of Clinical Oncology, 2014.
  41. \*Landier L, Chen Y, Namdar G, Francisco L, Wilson K, Herrera C, **Armenian SH**, Wolfson J, Sun CL, Wong FL, Bhatia S. Impact of tailored education in a survivorship clinic on childhood cancer survivor awareness of personal risk for therapy-related complications. European Symposium on Late Complications after Childhood Cancer, 2014.
  42. **Armenian SH**, Landier L, Francisco L, Herrera C, Mills G, Siyahian A, Supab N, Wilson K, Wolfson J, Horak D, Bhatia S. Comprehensive assessment of pulmonary health in a cohort of long-term childhood cancer survivors. European Symposium on Late Complications after Childhood Cancer, 2014.
  43. \***Armenian SH**, Xu L, Sun CL, Farol L, Bhatia S, Chao C. Prevalence and predictors of delayed cardiovascular disease among survivors of adults with hematologic malignancies. American Society of Hematology, 2014.
  44. \*Sun CL, Berano-The J, Halliday P, Hageman L, Ramamurthy M, **Armenian SH**, Gonzales A, Atencio L, Francisco L, Wong FL, Auayporn N, Chen R, O’Donnell MR, Rosenthal J, Popplewell L, Forman SJ, Bhatia R, Bhatia S. Do Changes in Transplant Practice influence Risk of Therapy-related Myelodysplasia/ Acute Myeloid Leukemia after Autologous Hematopoietic cell Transplantation (aHCT) for non-Hodgkin lymphoma (NHL)? American Society of Hematology, 2014.
  45. \*Arora M, Sun C, Ness KK, Berano Teh J, Schad A, Hanby C, Francisco L, Hou K, Wu J, Kuo L, **Armenian S**, Weisdorf D, Forman SJ, Bhatia S. Older Survivors of Allogeneic Hematopoietic Cell Transplantation (HCT) with Chronic Graft Vs. Host Disease (cGvHD) Demonstrate Higher Risk of Frailty As Compared with Autologous HCT Recipients: A Report from the Bone Marrow Transplant Survivor Study-2. Bone Marrow Transplantation Tandem Meetings, 2015.
  46. Wang X, Sun CL, Quiñones-Lombraña A, Singh P, Landier W, Hageman L, Mather M, Chen L, **Armenian SH**, Winick N, Ginsberg JP, Neglia JP, Oeffinger KC, Castellino SM, Dreyer Z, Hudson MM, Robison LL, Relling MV, Blanco JG, Bhatia S. *CELF4* variant and Anthracycline-related Cardiomyopathy – A COG Study (ALTE03N1). American Society of Clinical Oncology, 2015.
  47. \*Wang X, Sun CL, Quiñones-Lombraña A, Singh P, Landier W, Hageman L, Mather M, Chen L, **Armenian SH**, Winick N, Ginsberg JP, Neglia JP, Oeffinger KC, Castellino SM, Dreyer Z, Hudson MM, Robison LL, Relling MV, Blanco JG, Bhatia S. *CELF4* variant and Anthracycline-related Cardiomyopathy – A COG Study (ALTE03N1). International Conference on Long Term Complications of Treatment of Children and Adolescents for Cancer, 2015.
  48. \*Arora M, Sun C, Ness KK, Berano Teh J, Wu J, Francisco L, **Armenian SH**, Schad A, Namdar G, Bosworth A, Kuo L, Weisdorf DJ, Forman SJ, Bhatia S. Physiologic frailty among hematopoietic cell transplantation (HCT) survivors suggests accelerated aging and is a predictor for premature mortality: A

## Curriculum Vitae Saro H. Armenian, DO, MPH

report from the Bone Marrow Transplant Survivor Study (BMTSS). American Society of Hematology, 2015.

49. \*Chao C, Xu L, Cooper RM, Bhatia S, **Armenian SH**. Cardiovascular disease in adolescents and young adults with hematologic malignancies. American Society of Hematology, 2015.
50. \*Chen R, Palmer J, Martin P, **Armenian S**, Tsai N, Mott M, Sahebi F, Cai JL, Siddiqi T, Popplewell L, Nademanee A, Forman S. Post transplant outcome of a multicenter phase II study of brentuximab vedotin as first line salvage therapy in relapsed/refractory HL prior to AHCT. American Society of Hematology, 2015.
51. Mulder RL, Kremer LCM, Skinner R, Oeffinger KC, Bhatia S, Landier W, Levitt G, Constine LS, Wallace H, **Armenian SH**, Hudson MM. The International Late Effects of Childhood Cancer Guideline Harmonization Group. European Symposium on Late Complications after Childhood Cancer, 2016.
52. \*Wu J, Chen Y, Hageman L, Sun C-L, Francisco L, Ness E, Parman M, Watson JA, Weisdorf DJ, Snyder DS, McGlave P, Forman SJ, Arora M, **Armenian SH**, Bhatia R, Bhatia S. Long-term morbidity and mortality experienced by chronic myeloid leukemia (CML) patients after allogeneic hematopoietic cell transplantation (HCT). American Society of Hematology, 2016.
53. Wong FL, Berano-The J, Francisco L, Atencio L, Gonzales A, **Armenian S**, Forman SJ, Bhatia S. Impact of Self-Reported Pre-transplant Quality of Life (QOL) on Long-term Survival after Allogeneic or Autologous Hematopoietic Cell Transplantation (HCT). American Society of Hematology, 2016.
54. Nikolaenko L, **Armenian S**, Alvarnas J, Goldstein L, Zaia J, Goldstein L, Marroquin MV, Krishnan A. Long-term follow-up of patients with HIV-associated non-Hodgkin lymphoma after autologous stem cell transplantation. American Society of Hematology, 2016.
55. \*Chow EJ, Doody DR, **Armenian SH**, Aggarwal S, Baker KS, Bhatia S, Blythe N, Constine LS, Freyer DR, Kopp LM, Leisenring WM, Vrooman LM, Asselin BL, Schwartz CL, Lipshultz SE. Effect of Dexrazoxane on Heart Function among Long-Term Survivors of Childhood Leukemia and Lymphoma: a report from the Children's Oncology Group. American Society of Hematology, 2016.
56. \*Francisco L, **Armenian S**, Arora M, Chen Y, Wu J, Watson JA, Hageman L, Ness E, Parman M, Battles K, Sun CL, Bhatia R, Weisdorf DJ, Forman SJ, Bhatia S. Progressive decline in late mortality after hematopoietic cell transplantation (HCT) over the past 40 years – A report from BMTSS. American Society of Hematology, 2016.
57. Siyahian A, Kim H, Berano Teh J, Chang H, Atencio L, Gonzales A, Wong FL, Nakamura R, Sun CL, **Armenian SH**. Incidence and predictors of late-occurring central nervous system complications in allogeneic hematopoietic cell transplant survivors. American Society of Hematology, 2016.
58. \***Armenian SH**, Rinderknecht D, Au K, Lindenfeld L, Mills G, Siyahian A, Wilson K, Venkataraman K, Tavallali P, Razavi M, Pahlevan N, Detterich J, Bhatia S, Gharib M. Accuracy of a novel iPhone-based platform for detection of cardiomyopathy in anthracycline-exposed childhood cancer survivors. International Conference on Long Term Complications of Treatment of Children and Adolescents for Cancer, 2017
59. Bhatia S, Arora M, Chen Y, Costa LJ, Krishnan AY, Bhatia R, Wu J, Ness E, Kung M, Parman M, Francisco L, Hageman L, Weisdorf DJ, **Armenian SH**, Forman SJ. Trends in Cause-specific Late Mortality in patients with plasma cell dyscrasias treated with autologous hematopoietic cell transplantation – a report from BMTSS-2. American Society of Clinical Oncology, 2017.
60. Minasian M, Dimond E, Shelburne N, Desvigne-Nickens P, Davis M, Adhikari B, Fagerstrom R, Unger J, Fabian C, Floyd J, Douglas PS, Mustian K, Chow EJ, Lipshultz S, Hundley WG, **Armenian S**, Ky B. Evolving Cardio-Oncology Clinical Study Designs. Global Cardio-Oncology Summit, 2017
61. \*Holmqvist AS, Chen Y, Wu J, Hageman L, Francisco LF, Parman M, Kung M, Ness E, Battles K, Winther JF, Rosenthal J, Bhatia R, Salzman D, Forman S, Weisdorf D, **Armenian S**, Arora M, Bhatia S. Reduction

## Curriculum Vitae Saro H. Armenian, DO, MPH

- in Late Mortality after Autologous Blood or Marrow Transplantation (autoBMT) in Childhood – a Report from the Blood or Marrow Transplant Survivor Study-2 (BMTSS-2). American Society of Hematology, 2017.
62. \*Holmqvist AS, Chen Y, Wu J, Hageman L, Francisco LF, Parman M, Kung M, Ness E, Battles K, Bhatia R, Salzman D, Winther JF, Forman S, Rosenthal J, Weisdorf D, **Armenian S**, Arora M, Bhatia S. Decline in Late Mortality after Allogeneic Blood or Marrow Transplantation (alloBMT) performed in Childhood – a Report from the BMT Survivor Study-2 (BMTSS-2). American Society of Hematology, 2017.
  63. \*Arora M, Chen Y, Wu J, Hageman L, Francisco L, Ness E, Parman M, Kung M, Bosworth A, Nayar M, Bhatia R, Forman SJ, Weisdorf DJ, **Armenian SH**, Bhatia S. Morbidity associated with chronic Graft vs. Host Disease – a Blood or Marrow Transplant Survivor Study (BMTSS). American Society of Hematology, 2017.
  64. **Armenian SH**, Yang D, Berano Teh J, Lee B, Chang H, Mascarenhas K, Lee S, Iukuridze A, Xie JJ, Scott JM, Jones LW, Wong FL, Forman SJ, Nakamura R. Sarcopenia is a clinically relevant and independent predictor of adverse outcomes after allogeneic hematopoietic cell transplantation. American Society of Hematology, 2017.
  65. Kim E, Bhatia S, Hageman L, Wu J, Francisco L, Ness E, Parman M, Kung M, Bosworth A, Forman SJ, Weisdorf D, Arora M, **Armenian SH**, Kenzik K. High-intensity healthcare utilization by long-term survivors of allogeneic blood or marrow transplantation (BMT): A report from the BMT Survivor Study-2 (BMTSS-2). American Society of Hematology, 2017.
  66. \*Chao C, Xu L, Cannavale K, Wong FL, Huang PY, Cooper R, Bhatia S, **Armenian S**. Risk of subsequent malignant neoplasms in survivors of adolescent and young adult (AYA) lymphoma and leukemia. American Society of Hematology, 2017.
  67. Al Malki MM, Nathwani N, Yang D, Sandhu K, Salman J, Rouse M, Mokhtari S, Cao T, Dadwal S, Mei M, **Armenian S**, Parker P, Smith E, Donnell MO, Snyder D, Marcucci G, Nademanee A, Forman SJ, Stein A, Nakamura R. Melphalan-based Regimen is a Safe and Effective Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation in Patients Over the Age of 70 With Hematological Malignancies. American Society of Hematology, 2017.
  68. \*Chen RC, Palmer JM, Herrera AF, **Armenian SH**, Mei M, Popplewell L, Fueger A, Qasim I, Stiller T, Rosen ST, Forman SJ, Kwak LW. Phase II study of brentuximab vedotin plus ibrutinib for patients with relapsed/refractory Hodgkin lymphoma. American Society of Hematology, 2017.
  69. Zhu W, Wu Y, The JB, Ye N, Li H, Li H, Hmwe S, Jin T, Chen BB, **Armenian SH**. Clinical Knowledge Extraction from Literatures and EMR Patient Narratives Using Interactive Natural Language Processing Systems. American Medical Informatics Association, 2018.
  70. \*Wadhwa A, Chen Y, Wu J, Francisco L, Hageman L, Sällfors Holmqvist A, Ness E, Parman M, Battles K, **Armenian S**, Weisdorf DJ, Arora M, Orchard P, Miller W, Bhatia S. Late Mortality in Patients Transplanted for Inborn Errors of Metabolism – A Report from the Blood or Bone Marrow Transplant Survivor Study-2. Bone Marrow Transplantation Tandem Meetings, 2018.
  71. Pawlowska AB, Karras NA, Huaying L, DiMundo J, Cheng JC, Sun W, **Armenian S**, Yang D, Palmer JM, Bell A, Tegtmeyer B, Rosenthal J. Reactivation of Human Herpesvirus 6 in Pediatric Allogeneic Hematopoietic Stem Cell Transplant Recipients. Bone Marrow Transplantation Tandem Meetings, 2018.
  72. Dadwal SS, Nakamura R, Nathwani N, Yang D, Sandhu K, Salman J, Rouse M, Mokhtari S, Cao T, Mei M, Ali M, **Armenian S**, Parker P, Alvarnas J, Smith E, Donnell MO, Snyder D, Marcucci G, Nademanee A, Forman SJ, Stein A, Al Malikil MM. Infectious Complications in Older Adults Receiving Melphalan based Reduced Intensity Conditioning Regimen Allogeneic Hematopoietic Cell Transplantation with Hematological Malignancies. European Society for Blood and Marrow Transplantation, 2018.

**Curriculum Vitae**  
**Saro H. Armenian, DO, MPH**

73. \*Chen A, Lindenfeld L, Au K, Herrera C, Wilson K, Wong FL, **Armenian SH**. Prevalence and Risk Factors of Attrition from a Comprehensive Childhood Cancer Survivorship Clinic. Pediatric Academic Societies Meeting, 2018.
74. \*Bates JE, Keshavarz H, Rancati T, Yorke ED, Gagliardi G, Aznar MC, Moiseenko V, **Armenian S**, Kremer LC, Chen MH, van der Pal H, Cutter D, Constine LS, Hodgson D. Modeling Radiotherapy-Related Risk of Heart Failure in Survivors of Pediatric Malignancy: Early Results from the Pediatric Normal Tissue Effects in the Clinic Group. American Society for Radiation Oncology, 2018.
75. \*Border EL, Sachdeva R, Stratton KL, **Armenian SH**, Bhat A, Cox DE, Leger KJ, Leisenring WM, Meacham LR, Sadak KT, Sivanandam S, Nathan PC, Chow EJ. Longitudinal Change in Echocardiographic Parameters of Cardiomyopathy in Childhood Cancer Survivors: A Multicenter Study. American Society of Echocardiography, 2018.
76. Narayan HK, Putt M, Kosaraju N, Paz A, Bhatt S, Plappert T, Desai A, Mercer-Rosa L, **Armenian SH**, Omens JH, McCulloch AD, Womer RB, Ky B. Dexrazoxane Preferentially Mitigates Adverse Changes in Cardiac Structure and Function in Female Children with Sarcoma Receiving High-Dose Anthracycline Therapy. American Society of Echocardiography, 2018.
77. Aggarwal S, Chow EJ, Sasaki N, Doody DR, **Armenian SH**, Asselin BL, Constine LS, Schwartz CL, Vrooman LM, Lipshultz SE. Long-Term Cardioprotective Effects of Dexrazoxane Infusion During Anthracycline Chemotherapy: A Children's Oncology Group Speckle Echocardiography Study. American Society of Echocardiography, 2018.
78. Lipshultz ER, Chow EJ, Kopp LM, Doody DR, **Armenian SH**, Asselin BL, Baker KS, Bhatia S, Constine LS, Freyer DR, Schwartz CL, Lipshultz SE, Vrooman LM. Cardiometabolic risk in childhood cancer survivors: a Children's Oncology Group study. American Society of Clinical Oncology, 2018.
79. \*Scott JM, Li N, Liu Q, Yasui Y, Leisenring W, Nathan PC, Gibson T, **Armenian SH**, Nilsen TS, Oeffinger KC, Ness KK, Adams SC, Robison LL, Armstrong GT, Jones LW. Association of Exercise with Late Mortality in Adult Survivors of Childhood Cancer: A Report from the Childhood Cancer Survivor Study. American Society of Clinical Oncology, 2018.
80. \*Chao C, Xu L, Cannavale K, Wong FL, Huang PS, Cooper R, Bhatia S, **Armenian S**. Risk of chronic comorbidities in survivors of adolescent and young adult cancer. American Society of Clinical Oncology, 2018.
81. \*Zhu W, Berano Teh J, Li H, **Armenian SH**. Knowledge Extraction of Long-term Complications from Clinical Narratives Using Linguamatics I2. American Medical Informatics Association Symposium, 2018.
82. \*Gangaraju R, Chen Y, Hageman L, Wu J, Francisco L, Kung M, Ness E, Parman M, Weisdorf DJ, Forman SJ, Arora M, **Armenian SH**, Bhatia S. Venous Thromboembolism in Blood or Marrow Transplant Survivors: A Report from the BMTSS. American Society of Hematology, 2018.
83. \*Farrukh N, Hageman L, Chen Y, Wu J, Ness E, Kung M, Francisco L, Parman M, Landier W, Arora M, **Armenian S**, Williams G, Bhatia S. Chronic Severe Pain and Prescription Pain Medication Use in Older Survivors of Hematologic Malignancies (HM) several years after treatment with Blood or Marrow Transplantation (BMT) – A Report from BMTSS. American Society of Hematology, 2018.
84. \*Wong FL, Xiao M, Berano-The J, Atencio L, Gonzales A, Hinton A, Iukuridze D, Forman SJ, Nakamura R, **Armenian S**. Conditional survival and mortality risks after allogeneic hematopoietic cell transplantation (alloHCT) in patients who survived varying lengths of time after alloHCT. American Society of Hematology, 2018.
85. \*A Iukuridze, M Xiao, J Berano Teh, K Mascarenhas, J McCune, J Zain, R Chen, L Popplewell JM Scott, LW Jones, SJ Forman, R Nakamura, FL Wong, **Armenian SH**. Muscle depletion is an important and clinically relevant predictor of outcomes after autologous hematopoietic cell transplantation. American Society of Hematology, 2018.

**Curriculum Vitae**  
**Saro H. Armenian, DO, MPH**

86. Arora M, Chen Y, Hageman L, Wu J, Francisco L, Kung M, Ness E, Parman M, Weisdorf DJ, Forman SJ, **Armenian SH**, Bhatia S. Burden of Morbidity Borne by Survivors of Multiple Myeloma (MM) treated with Autologous Blood or Marrow Transplant – Results of the BMT Survivor Study. American Society of Hematology, 2018.
87. \*Bates J, Keshavarz H, Rancati T, Yorke E, Gagliardi G, Aznar M, Moiseenko V, **Armenian S**, Kremer L, Chen MH, Ronckers C, van der Pal H, Cutter D, Constine L, Hodgson D. Modeling Radiation Therapy-Related Risk of Heart Failure in Survivors of Pediatric Malignancy Early Results from the Pediatric Normal Tissue Effects in the Clinic Group. American Society for Radiation Oncology, 2018.
88. McCune JS, Randolph TW, Deeg HJ, Risler LJ, **Armenian S**, Nakamura R, Men A, Quinones CM, van Maarseveen EM, Baker KS. Prediction of GVHD and relapse by metabolomic biomarkers before hematopoietic cell transplant recipients. Gordon Research Conference, 2018.
89. \*Sachdeva R, Stratton KL, **Armenian SH**, Bhat A, Border WL, Cox DE, Leger KJ, Leisenring WM, Meacham LR, Sadak KT, Sivanandam S, Nathan PC, Chow EJ. Unique Challenges Associated with a Large Repository of Clinical Echocardiograms from a Multicenter Retrospective Cohort of Childhood Cancer Survivors: Lessons Learned from Central Core Lab Analysis. American Society of Echocardiography, 2019.
90. Ehrhardt MJ, Ward ZJ, Liu Q, Chaudhry A, Nohria A, Border W, Robison LL, Armstrong GT, Yasui Y, Hudson MM, Diller LR, **Armenian SH**, Yeh JM. Cost-effectiveness of screening guidelines to prevent heart failure in childhood cancer survivors. American Society of Clinical Oncology, 2019.
91. McDonald A, Chen Y, Wu J, Hageman L, Francisco L, Kung M, Ness E, Landier W, Battles K, Salzman D, Weisdorf DJ, Forman SJ, Arora M, **Armenian SH**, Bhatia S. Total body irradiation and risk of breast subsequent malignant neoplasm after blood or marrow transplantation: a report from the BMT survivor study. American Society of Clinical Oncology, 2019.
92. Jang S, Zahrieh D, Ruddy KJ, **Armenian SH**, Lenihan D, Loprinzi C, Herrmann J. Systematic Review and Meta-Analysis of Definitions and Reported Incidences of Anthracycline Cardiotoxicity. American Society of Clinical Oncology, 2019.
93. \*Ehrhardt MJ, Ward ZJ, Liu Q, Chaudhry A, Nohria A, Border W, Robison LL, Armstrong GT, Yasui Y, Hudson MM, Diller LR, **Armenian SH**, Yeh JM. Cost-effectiveness of screening guidelines to prevent heart failure in childhood cancer survivors. North American Symposium on Late Complications after Childhood Cancer, 2019.
94. \*Bates J, Keshavarz H, Rancati T, Gagliardi G, Aznar M, Moiseenko V, Yorke E, **Armenian S**, Kremer L, Chen MH, van der Pal H, Cutter D, Constine L, Hodgson D. Modeling Radiation Therapy-Related Cardiac Disease in Childhood Cancer Survivors Treated with Radiotherapy: Final Results from the PENTEC Group. American Society for Radiation Oncology, 2019.
95. Chang EK, Berano The J, Peng K, Kim H, Nakamura R, Forman SJ, **Armenian SH**, Cai L. Risk factors for atrial fibrillation in patients undergoing allogeneic hematopoietic cell transplantation. American Heart Association, 2019.
96. Slavin TP, Berano Teh J, Weitzel JN, Peng K, Wong FL, Qin H, Wang J, Wu X, Pilai R, Wang Y, Wing Tsang KK, PozhitkovX A, Krishnan A, Forman SJ, **Armenian SH**. Association between clonal hematopoiesis and non-relapse mortality after autologous hematopoietic cell transplantation for lymphoma. American Society of Human Genetics, 2019
97. \***Armenian SH**, Chen Y, Hageman L, Wu J, Francisco L, Kung M, Ness E, Parman M, Weisdorf DJ, Forman SJ, Arora M, Bhatia S. Burden of Long-term Morbidity borne by Survivors of Acute Myeloid Leukemia (AML) treated with Blood or Marrow Transplantation (BMT) – Results of the BMT Survivor Study (BMTSS). American Society of Hematology, 2019.
98. Berano Teh J, Abdulla F, Peng K, Atencio L, Echevarria M, Iukuridze A, Kim H, Geller A, Wong FL, Forman S, Nakamura R, Modi B, **Armenian SH**. Incidence and Risk Factors of de novo Skin Cancer in a

## Curriculum Vitae Saro H. Armenian, DO, MPH

Contemporary Cohort of Hematopoietic Cell Transplantation Survivors. American Society of Hematology, 2019.

99. \*Herrera AF, Chen L, Popplewell L, Budde E, Mei M, **Armenian S**, Darrach J, Nikolaenko L, Chen R, Kennedy N, Rosen S, Forman S, Kwak L. Preliminary Results from a Phase I Trial of Pembrolizumab Plus Vorinostat in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma, Follicular Lymphoma, and Hodgkin Lymphoma. American Society of Hematology, 2019.
100. \*Arora M, Chen Y, Wu J, Hageman L, Ness E, Kung M, Francisco L, Bosworth A, Weisdorf DJ, Forman SJ, Wong FL, Landier W, **Armenian SH**, Bhatia S. Longitudinal Trajectory of Frailty in Blood or Marrow Transplant (BMT) Survivors – a BMT Survivor Study. American Society of Hematology, 2019.
101. S Bhatia, L Hageman, W Landier, K Smith, H Umphrey, C Reich, K Zamora, S Ahmed, **SH Armenian**, T Bartholomew Bevers, A Blaes, T Henderson, D Hodgson, MM Hudson, L Korde, S Melin, S Merjaver, L Overholser, S Pruthi, J Garber. Effect of Low-dose Tamoxifen (LDTam) on Mammographic Breast Density (MBD) in Lymphoma Survivors exposed to Chest Radiation Therapy (RT) during Childhood, Adolescence and Young Adulthood – a randomized, placebo-controlled double blinded phase IIb trial to reduce risk of radiation-related breast cancer (BC). American Society of Hematology, 2019.
102. Gangaraju R, Chen Y, Hageman L, Wu J, Landier W, Francisco L, McDonald A, Murdaugh D, Kung M, Ness E, Weisdorf DJ, Forman SJ, Wong FL, Arora M, **Armenian SH**, Bhatia S. Stroke Risk in Blood or Marrow Transplant (BMT) Survivors – a report from the BMT Survivor Study (BMTSS). American Society of Hematology, 2019.
103. Chow EJ, Doody DR, Di C, **Armenian SH**, Bricker JB, Gopal AK, Hagen A, Ketterl TG, Reding KW, Syrjala KL, Taylor SL, Wang G, Neuhaus ML, Mendoza JA. Feasibility of Using mHealth Activity and Dietary Trackers in Combination with Social Media to Enhance Survivorship Care and Improve Lifestyle Factors associated with Cardiovascular Disease. American Society of Preventive Oncology, 2020.
104. Weil B, Green DM, Murphy AJ, Liu Q, Howell RM, Weldon CB, Dieffenbach BV, Mullen EA, Madenci AL, Leisenring WM, Neglia JP, Oeffinger KC, Termuhlen AM, Mostoufi-Moab S, Levine JM, Krull KR, Yasui Y, Robison LL, Armstrong GT, Chow EJ, **Armenian SH**. Chronic health conditions and late mortality among long-term survivors of Wilms tumor treated with modern regimens: A report from the Childhood Cancer Survivor Study. American Society of Clinical Oncology, 2020.
105. Giri S, Chen Y, Hageman L, Wu J, Francisco L, Bosworth A, Costa LJ, Weisdorf DJ, Forman SJ, **Armenian SH**, Arora M, Bhatia S. Decline in Cause-specific Late Mortality among Multiple Myeloma (MM) patients treated with Autologous Peripheral Blood Stem Cell Transplantation – a BMTSS report. American Society of Clinical Oncology, 2020.
106. \*Chow EJ, Aggarwal S, Doody DR, Aplenc R, **Armenian SH**, Bajer KS, Bhatia S, Blythe N, Colan SD, Constine LS, Freyer DR, Kopp LM, Laverdiere C, Leisenring WM, Sasaki N, Vrooman LM, Asselin BL, Schwartz CL, Lipshultz SE. Dexrazoxane and Heart Function among Long-Term Childhood Cancer Survivors: a Children’s Oncology Group study. American Society of Clinical Oncology, 2020.
107. Landier W, Bhatia S, Wong FL, York JM, Flynn JS, Wasilewski-Masker K, Cherven B, Connelley JA, Jasty-Rao R, Leonard M, **Armenian SH**, Robison LL, Giuliano A, Hudson MM, Klosky JL. Immunogenicity and safety of the 3-dose Human Papillomavirus (HPV) vaccine series in young cancer survivors. American Society of Clinical Oncology, 2020.
108. \*Holmqvist AS, Chen Y, Wu J, Hageman L, Battles K, Francisco LF, Kung M, Goldman F, Rosenthal J, Forman S, Weisdorf D, Arora M, **Armenian S**, Bhatia S. Severe/Life-threatening/Fatal Chronic Health Conditions (CHCs) after Allogeneic Blood or Marrow Transplantation (BMT) in Childhood – a Report from the BMT Survivor Study (BMTSS). American Society of Hematology, 2020.
109. \*Herrera AF, Chen L, Nieto Y, Holmberg L, Johnston P, Mei M, Popplewell L, **Armenian S**, Cao T, Farol L, Sahebi F, Spielberger R, Chen R, Nademanee A, Kennedy N, Peters L, Rosen S, Kwak L, Forman S,

## Curriculum Vitae Saro H. Armenian, DO, MPH

- Feldman T. Consolidation with Nivolumab and Brentuximab Vedotin After Autologous Hematopoietic Cell Transplantation in Patients with High-Risk Hodgkin Lymphoma. American Society of Hematology, 2020.
110. \*Gangaraju R, Chen Y, Hageman L, Wu J, Francisco L, Kung M, Weisdorf DJ, Forman SJ, Arora M, **Armenian SH**, Bhatia S. Coronary Heart Disease Risk in Blood or Marrow Transplant Survivors. American Society of Hematology, 2020.
111. Wadhwa A, Chen Y, Holmqvist AS, Wu J, Hageman L, Francisco L, Battles K, Balas N, Kung M, **Armenian S**, Arora M, Bhatia S. Chronic Health Conditions (CHCs) after Allogeneic Blood or Marrow Transplantation (BMT) for Inborn Errors of Metabolism (IEM) – A BMT Survivor Study (BMTSS) Report. Transplantation and Cellular Therapy Meeting, 2021.
112. Murdaugh D, Sharafeldin N, Hageman L, Wu J, Bosworth A, Landier W, Weisdorf D, Forman SJ, **Armenian S**, Arora M, Bhatia S. Association between learning and memory problems and health outcomes after blood or marrow transplantation (BMT): a BMT survivor study (BMTSS) report. American Society of Clinical Oncology, 2021.
113. Bottinor W, Im C, **Armenian SH**, Hong B, Howell R, Ness KK, Oeffinger KC, Armstrong GT, Yasui Y, Chow EJ. Overall and cardiac-specific survival following serious cardiovascular events in childhood cancer survivors. American Society of Clinical Oncology, 2021.
114. Border WL, Sachdeva R, Stratton KL, **Armenian SH**, Bhat A, Cox DE, Leger KJ, Leisenring WM, Meacham LR, Sadak KT, Sivanandam S, Nathan PC, Chow EJ. Utility of Apical Four-Chamber Longitudinal Strain in the Assessment of Childhood Cancer Survivors: A Multicenter Study. American Society of Echocardiography, 2021.
115. \*Kenney L, Nohria A, Moss K, Ehrhardt M, Nekhlyudov, L, Yock T, **Armenian SH**, Ames B, Margossian R. Screening and interventions for childhood cancer survivors at risk for cardiomyopathy: consensus and controversy. International Society of Pediatric Oncology, 2021.
116. \*Wolfson J, Bhatia S, Hageman L, Schlichting E, Balas N, Bosworth A, Sreng Te H, Francisco L, Funk E, Hicks J, Landier W, Wu J, Siler A, Armenian S, Arora M, Aswani M. Association between Neighborhood Disadvantage and Health Status/Healthcare Utilization in Survivors of Blood or Marrow Transplantation (BMT) – a BMTSS Report. American Society of Hematology, 2021.
117. Balas N, Hageman L, Landier W, Schlichting E, Bosworth A, Sreng Te J, Wu J, Francisco L, Wong FL, Bhatia R, Salzman D, Goldman F, Weisdorf DJ, Forman SJ, Arora M, **Armenian SH**, Bhatia S. Conditioning Intensity and Probability of Livebirth after Blood or Marrow Transplantation – a Report from the BMT Survivor Study. American Society of Hematology, 2021.
118. McDonald A, Dai C, Hageman L, Landier W, Wu J, Schlichting E, Balas N, Francisco L, Bosworth A, Sreng Te H, Wong FL, Salzman D, Bhatia R, Weisdorf DJ, Forman SJ, Arora M, **Armenian SH**, Bhatia S. Subsequent Malignant Neoplasms of the Gastrointestinal Tract after Blood or Marrow Transplantation – a BMTSS report. American Society of Hematology, 2021.
119. \*Arora M, Dai C, Landier L, Hageman L, Wu J, Schlichting E, Siler A, Funk E, Hicks J, Balas N, Bosworth A, Sreng Te H, Francisco L, Bhatia R, Salzman D, Goldman FD, Forman SJ, Weisdorf DJ, Wong FL, **Armenian SH**, Bhatia S. Trends in Late Mortality and Life Expectancy after Autologous Blood or Marrow Transplantation performed over Three Decades – a BMT Survivor Study Report. American Society of Hematology, 2021.
120. \*Herrera AF, Chen L, Budde E, **Armenian S**, Nikolaenko L, Chen R, Daniels S, Kennedy N, Peters L, Rosen S, Forman S, Popplewell L, Kwak L, Mei M. Pembrolizumab Plus Vorinostat Induces Responses in Patients with Hodgkin Lymphoma Who Are Refractory to Prior PD-1 Blockade. American Society of Hematology, 2021.
121. \*Bhandari R, Teh JB, Nakamura R, Artz A, Forman SJ, Wong FL **Armenian SH**. Social Vulnerability Is a Clinically Important Predictor of Outcomes after Allogeneic Hematopoietic Cell Transplantation. American Society of Hematology, 2021.

**Curriculum Vitae**  
**Saro H. Armenian, DO, MPH**

122. Iukuridze A, Berano Teh J, Ramos J, Cabrera Vera T, Lee K, Bhandari R, Artz AS, Budde E, Herrera AF, Popplewell LL, Shouse G, Siddiqi T, Forman SJ, Wong FL, **Armenian SH**. Sarcopenia is a clinically relevant and independent predictor of health outcomes after chimeric antigen receptor T-cell therapy. American Society of Hematology, 2021.
123. van den Oever SR, Pluijm SMF, Skinner R, Glaser A, Mulder RL, **Armenian S**, Bardi E, Berger C, Ehrhardt M, Winther JF, Marchak JG, den Hartog J, Haeusler G, Hjorth L, Kepak T, Márquez C, Michel G, Muraca M, Najib M, Panasiuk A, Roganovic J, Uyttebroeck A, Zaletel L, van Dalen EC, van der Pal H, Hudson MM, Kremer LCM on behalf of the IGHG COVID-19 working group. Childhood Cancer Survivorship Care during the COVID-19 pandemic: An International Report of Practice Implications and Provider Concerns. International Society of Pediatric Oncology, 2021.
124. Wadhwa A, Dai C, Hageman L, Wu J, Schlichting E, Te HS, Bosworth A, Balas N, Siler A, Funk E, Hicks J, Francisco L, Wong FL, Forman SJ, Weisdorf DJ, **Armenian SH**, Arora M, Bhatia S. Conditioning Intensity and Chronic Health Conditions (CHCs) after Allogeneic Blood or Marrow Transplantation (BMT): A Report from the BMT Survivor Study (BMTSS). Transplant & Cellular Therapy Meetings, 2022.
125. Lee K, Flores A, Albanese S, Atencio L, Echevarria M, Shamunee J, Lindenfeld L, Jamal F, Wong FL, **Armenian S**. Cardiovascular Reserve Capacity in Patients Undergoing Hematopoietic Cell Transplantation. American College of Sports Medicine, 2022.
126. Audino A, Xavier AC, Hochberg JC, Barth M, Miles R, Kahwash S, Voss SD, Braniecki S, Moorthy C, **Armenian SH**, Ehrhardt M, Lim MS, Harrison L, Goldman S, Cairo M. Reducing the Burden of Oncology Chemoradiotherapy And Radiation Exposure from Diagnostic Imaging by Utilizing Targeted Immunotherapy in Children, Adolescents and Young Adults (CAYA) with Lymphoma (RADICAL). A Pediatric Ohio-New York Cancer (PedONC) ImmunoRx Center Clinical Trial. American Society of Pediatric Hematology/Oncology, 2022.
127. Ji J, Sun CL, Dale W, Cohen HJ, Muss HB, Magnuson A, O'Connor TL, Freedman RA, Katheria V, **Armenian S**, Sedrak MS. Functional decline in older breast cancer survivors treated with and without chemotherapy and non-cancer controls. American Society of Clinical Oncology, 2022.
128. Hayek S, Lebresco G, Chao C, Xu L, Cavanale K, Barda N, Izraeli S, **Armenian S**. The burden of long-term complications among adolescent and young adult cancer survivors: An international comparison of two large cohorts. American Society of Clinical Oncology, 2022.
129. Giri S, Harmon C, Hageman L, Bosworth A, Te HS, Ross E, Balas N, Dai C, Williams GR, Landier W, Arora M, Forman SJ, **Armenian S**, Weisdorf DJ, Bhatia S. Baseline body composition and subsequent long-term chronic health conditions among lymphoma patients treated with autologous peripheral blood stem cell transplantation – a BMTSS report. American Society of Clinical Oncology, 2022.
130. Xavier AC, Hochberg JC, Audino A, Barth M, Miles R, Kahwash S, Voss SD, Braniecki S, Moorthy C, **Armenian SH**, Ehrhardt M, Lim MS, Harrison L, Goldman S, Cairo M. Reducing the Burden of Oncology Chemoradiotherapy And Radiation Exposure from Diagnostic Imaging by Utilizing Targeted Immunotherapy in Children, Adolescents and Young Adults (CAYA) with Lymphoma (RADICAL). A Pediatric Ohio-New York Cancer (PedONC) ImmunoRx Center Clinical Trial. International Society of Pediatric Oncology, 2022.
131. \*De Baat EC, van Dalen EC, Mulder RL, Hudson MM, Ehrhardt MJ, Engels FK, Feijen EAM, Grotenhuis HB, Leerink JM, Kapusta L, Kaspers GJL, Merks R, Mertens L, Skinner R, Tissing WJE, de Vathaire F, Nathan PC, Kremer LCM, Mavinkurve-Groothuis AMC, **Armenian SH**. Primary cardioprotection with dexrazoxane in childhood cancer patients expected to receive anthracyclines: recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group. International Society of Pediatric Oncology, 2022.
132. Shrestha S, Liu Q, Bates JE, Smith SA, Oeffinger KC, Chow EJ, Constine LS, Robison L, Ness K, Ehrhardt M, Jefferies J, **Armenian S**, Paulino AC, Pinnix CC, Court LE, Kry SF, Hudson MM, Armstrong GT, Mulrooney DA, Yasui Y, Howell RM. Development and validation of risk prediction models for



## Curriculum Vitae Saro H. Armenian, DO, MPH

cardiovascular diseases that include radiotherapy dose-volume metrics in survivors of childhood cancer. Radiation Research Society, 2022.

133. Kambhampati S, Mei M, Chen L, Puvurel S, Chen R, Popplewell L, Nikolaenko L, Peters L, **Armenian S**, Kwak L, Rosen S, Forman S, Herrera A. Phase I Trial of Brentuximab Vedotin plus Cyclosporine in Relapsed/Refractory Hodgkin Lymphoma. American Society of Hematology, 2022.
134. \*Holmqvist AS, Meng Q, Dai C, Hageman L, Landier W, Wu J, Francisco LF, Ross ES, Balas N, Bosworth A, Te HS, Bhatia R, Rosenthal J, Wong FL, Weisdorf DJ, **Armenian SH**, Bhatia S. Late Morbidity and Mortality after Autologous Blood or Marrow Transplantation (BMT) for Lymphoma in Children, Adolescents and Young Adults – a Report from the BMT Survivor Study. American Society of Hematology, 2022.
135. Buchbinder D, Bhatt NS, Wang H, Yasui Y, **Armenian S**, Bhatia S, Chow EJ, Huang IC, Kirchoff AC, Leisenring W, Yabroff KR, Armstrong GT, Nathan PC, Khera N. A comparison of financial hardship among survivors of childhood cancer treated with or without hematopoietic cell transplantation: A report from the Childhood Cancer Survivor Study. American Society of Hematology, 2022.
136. Gangaraju R, Chen Y, Hageman L, Landier W, Balas N, Ross E, Francisco L, Bosworth A, Te HS, Wong FL, Weisdorf DJ, Bhatia R, Forman SJ, **Armenian SH**, Bhatia S. Individual Prediction of Cardiovascular Events in Blood or Marrow Transplant (BMT) Survivors - a BMT Survivor Study (BMTSS) Report. American Society of Hematology, 2022.
137. Perez JR, Shan H, Yang D, Chien L, Uranga C, Salman J, Dale W, Aldoss I, Ali H, Aribi A, **Armenian S**, Arslan S, Pullarkat V, Salhotra A, Sandhu K, Spielberger R, Stein A, Marcucci G, Forman SJ, Al Malki M, Nakamura R, Artz A. Disability-free Survival (DiFS): A novel early healthspan endpoint for older patients receiving allogeneic hematopoietic cell transplantation (HCT). American Society of Hematology, 2022.
138. \*Bhatia S, Yan C, Richard MA, He J, Bosworth A, Crossman D, Singh P, Hageman L, **Armenian SH**, Vose J, Weisdorf DJ, Yasui Y, Ebert BL, Gibson CJ, Forman SJ, Bhatia R. Specific Clonal Mutations are Predictive of Therapy-related Myeloid Neoplasms (tMN) after Autologous Peripheral Blood Stem Cell Transplantation (aPBSCT) for Lymphoma. American Society of Hematology, 2022.
139. \*Zhang L, Dong H, Lin Y, Hu W, Salhorta A, **Armenian S**, Marcucci G, Li L. Targeting *SAMHD1* promotes anti-tumor immunity in Acute Myeloid Leukemia. American Society of Hematology, 2022.
140. Rhee JW, Pillai R, He T, Bosworth A, Iukuridze A, Lindenfeld L, Goldsmith S, Rosenzweig M, Natarajan P, Krishnan A, Wong FL, Forman SJ, **Armenian SH**. Clonal hematopoiesis is associated with cardiovascular disease in patients with multiple myeloma undergoing hematopoietic cell transplantation. American Association for Cancer Research, 2023.
141. Henderson TO, Bardwell JK, Kao P, Nathan PC, Landier W, Mostoufi-Moab S, Brinkman T, Park J, **Armenian S**, Naranjo A, Subramaniam M, Marachelian A, Diskin S, London WB, Diller L. A Multicenter Cooperative Group Study of Late Effects After High-Risk Neuroblastoma (COG ALTE15N2/ LATE EFFECTS AFTER HIGH-RISK NEUROBLASTOMA (LEAHRN) STUDY). American Society of Clinical Oncology, 2023.
142. **Armenian SH**, Hudson MM, Lindenfeld L, Chen S, Chow EJ, Colan S, Collier W, Echevarria M, Iukuridze A, Robison LL, Chen MH, Bhatia S. Carvedilol for Prevention of Heart Failure in Anthracycline-Exposed Survivors of Childhood Cancer: Results from COG ALTE1621. American Society of Clinical Oncology, 2023.
143. Sharafeldin N, Wang X, Wang F, Singh P, Zhou L, Landier W, Hageman L, Burrige PW, Yasui Y, Sapkota Y, Oeffinger K, Hudson MM, Chow EJ, **Armenian SH**, Neglia JP, Ritchey AK, Hawkins DS, Ginsberg JP, Robison LL, Armstrong GT, Bhatia S. Polygenic risk of anthracycline-related cardiomyopathy in childhood cancer survivors: report from Children's Oncology Group and Childhood Cancer Survivor Study. American Society of Clinical Oncology, 2023.
144. Chow EJ, Stratton KL, **Armenian SH**, Bhat A, Edwards LM, Boyle PM, Leger KJ, Meacham LR, Nathan PC, Sadak KT, Narasimhan S, Sachdeva R, Border WL, Leisenring WM. Enhanced prediction of cancer

## Curriculum Vitae

### Saro H. Armenian, DO, MPH

therapy-related cardiomyopathy from surveillance echocardiograms: a Children's Oncology Group (COG) report. American Society of Clinical Oncology, 2023.

145. Abu Rmilah A, Kailash V, Farooqyu N, Jang S, Ruddy KJ, Armenian S, Lenihan DJ, Loprinzi CL, Herrmann J. Anthracycline-related cardiotoxicity among lymphoma patients: systematic review and meta-analysis. American Society of Clinical Oncology, 2023.
146. Henderson TO, Bardwell JK, Kao P, Nathan PC, Landier W, Mostoufi-Moab S, Brinkman T, Park J, **Armenian S**, Naranjo A, Subramaniam M, Marachelian A, Diskin S, London WB, Diller L. A Multicenter Cooperative Group Study of Late Effects After High-Risk Neuroblastoma (COG ALTE15N2/LATE EFFECTS AFTER HIGH-RISK NEUROBLASTOMA (LEAHRN) STUDY). International Symposium on Late Complications After Childhood Cancer, 2023.
147. **Armenian SH**, Hudson MM, Lindenfeld L, Chen S, Chow EJ, Colan S, Collier W, Echevarria M, Iukuridze A, Robison LL, Chen MH, Bhatia S. Carvedilol for Prevention of Heart Failure in Anthracycline-Exposed Survivors of Childhood Cancer: Results from COG ALTE1621. International Symposium on Late Complications After Childhood Cancer, 2023.
148. Sharafeldin N, Wang X, Wang F, Singh P, Zhou L, Landier W, Hageman L, Burrige PW, Yasui Y, Sapkota Y, Oeffinger K, Hudson MM, Chow EJ, **Armenian SH**, Neglia JP, Ritchey AK, Hawkins DS, Ginsberg JP, Robison LL, Armstrong GT, Bhatia S. Polygenic risk of anthracycline-related cardiomyopathy in childhood cancer survivors: report from Children's Oncology Group and Childhood Cancer Survivor Study. International Symposium on Late Complications After Childhood Cancer, 2023.
149. Chow EJ, Stratton KL, **Armenian SH**, Bhat A, Edwards LM, Boyle PM, Leger KJ, Meacham LR, Nathan PC, Sadak KT, Narasimhan S, Sachdeva R, Border WL, Leisenring WM. Enhanced prediction of cancer therapy-related cardiomyopathy from surveillance echocardiograms: a Children's Oncology Group (COG) report. International Symposium on Late Complications After Childhood Cancer, 2023.

*\*Denotes oral presentation*

### **Book Chapters**

1. **Armenian SH**, Meadows AT, Bhatia S. Late effects of childhood cancer. Principles and Practice of Pediatric Oncology. Pizzo and Poplack. 6th Edition, 2009.
2. **Armenian S**. Physical activity and cardiotoxic therapies. Pediatric Oncology Exercise Manual (POEMS). Eds: Chamorro-Vina, Keats, Culos-Reed. 1<sup>st</sup> Edition, 2014.
3. Landier W, **Armenian SH**, Meadows AT, Bhatia S. Late effects of childhood cancer and its treatment. Principles and Practice of Pediatric Oncology. Pizzo and Poplack. 7th Edition, 2015.
4. Chow EJ, **Armenian SH**. Cancer Survivorship and Recommendations for Follow-Up. Rudolph's Pediatrics. 23<sup>rd</sup> Edition, 2016.
5. Landier W, **Armenian SH**, Gramatges MM, Chow EJ, Bhatia S. Late Effects of Childhood Cancer and Its Treatment. Pizzo and Poplack. 8th Edition, 2019.

### **Invited Lectures (selected)**

"Role of genetic susceptibility in the development of cardiac complications after HSCT"  
Educational session, BMT Tandem Meetings, February 2010.

"Cardiovascular outcomes in childhood and adult-onset cancer: evolving paradigms"  
Pediatric Grand Rounds, City of Hope, April 2010.

"Health risks associated with treatment of cancer during childhood and adolescence"  
Children's Oncology Group, Education Session, September 2010.

## **Curriculum Vitae** **Saro H. Armenian, DO, MPH**

- “Cardiac complications as late effects of hematopoietic cell transplantation”  
Pediatric Blood and Marrow Transplant Consortium, NIH Late Effects Consensus Conference, April 2011.
- “Current controversies in transplantation for pediatric acute leukemias”  
Educational session, ASCO annual meeting, June 2011.
- “Cardiovascular disease in survivors of childhood cancer: evolving paradigms”  
The Pablove Foundation Childhood Cancer Survivorship Symposium, November 2011.
- “Hodgkin lymphoma in childhood and adolescence”  
Leukemia & Lymphoma Society Blood Cancer Conference, January 2013.
- “Cardiovascular disease in survivors of childhood cancer: evolving paradigms”  
Grand Rounds, St. Jude Children’s Research Hospital, March 2013.
- “Cardiovascular disease in survivors of childhood cancer: novel insights into pathophysiology, screening, and prevention”; Education Symposium, ASPHO Annual Meeting, April 2013.
- “Prevention strategies for childhood cancer survivors at risk for cardiovascular disease”  
Education Symposium, ASPHO Annual Meeting, April 2013.
- “Cardiovascular health of cancer survivors”  
Department of Cardiology Grand Rounds, Kaiser Permanente Southern California, May 2013.
- “Atherosclerosis in cancer patients: what’s at the heart of the matter?”  
Department of Populations Sciences Grand Rounds, City of Hope, December 2013
- “Health-related outcomes in survivors of childhood hematopoietic cell transplantation”  
Pediatric Oncology Group of Ontario AfterCare Education Day, February 2014.
- “Key therapy-related adverse events: from etiology to risk-reduction strategies - cardiac morbidity”  
Current Concepts in Epidemiology and Prevention Research Session, AACR Annual Meeting, April 2014.
- “Long-term health-related outcomes in survivors of childhood hematopoietic cell transplantation”  
Department of Populations Sciences Grand Rounds, City of Hope, April 2014
- “Risk reduction strategies in childhood cancer survivors treated with high dose anthracyclines”  
Leukemia & Lymphoma Society, Research Symposium, May 2014
- “International harmonization on cardiomyopathy screening for childhood cancer survivors”  
European Symposium on Late Complications after Childhood Cancer, September 2014
- “Late effects of treatment in pediatric soft tissue sarcoma”  
Pablove symposium on pediatric soft tissue sarcomas, November 2014
- “Transition of care in childhood cancer survivors: monitoring for late effects of therapy”  
American College of Cardiology, Cardio-Oncology Intensive Seminar, March 2015.
- “The price of cure: long-term outcomes in adult survivors of childhood cancer”  
Education Session, AACR Annual Meeting, April 2015
- “Cardiovascular disease in childhood cancer survivors: from etiology to risk-reduction strategies”  
20<sup>th</sup> Ludwina I. Knapp Memorial Lecture, Mercy Children’s Hospital, May 2015
- “Examining late effects and overall health of pediatric cancer survivors”  
Pediatric oncology session, ASCO Annual meeting, June 2015
- “Translating survivorship research into health surveillance guidelines”  
Education Session, ASCO Annual Meeting, June 2015
- “Cardiovascular morbidity in AYA cancer survivors”, “Health risks associated with treatment for AYAs”  
Education Session, Lymphoma Research Foundation, October 2015

## Curriculum Vitae Saro H. Armenian, DO, MPH

“Screening and prevention of cardiomyopathy in childhood cancer survivors”  
Global Cardio-Oncology Summit, October 2015

“Cardiovascular disease in childhood cancer survivors: from etiology to risk-reduction strategies”  
Hematology/Oncology Grand Rounds, Texas Children’s Hospital, October 2015

“Cardiovascular morbidity in cancer survivors”  
Cancer Center Grand Rounds, University of Alabama at Birmingham, October 2015

“Cardiovascular disease in childhood cancer survivors: from etiology to risk-reduction strategies”  
Hematology, Oncology and BMT Research Seminar, Children’s Hospital Los Angeles, November 2015

“Anthracycline-induced cardiotoxicity in young cancer patients: the role of carnitine”  
First international carnitine working group meeting, Rome, IT, December 2015.

“Late effects of transplants: lessons learned and strategies to improve the health of the HCT survivor”  
Kaiser Permanente Transplant Symposium, March 2016

“Cardiovascular disease and cancer: emerging paradigms in biology, prevention, and treatment”  
Center for Childhood Cancer Research, Children’s Hospital of Philadelphia, April 2016

“Cardiovascular disease in childhood cancer survivors: from etiology to risk-reduction strategies”  
Keynote, 7<sup>th</sup> International Nursing Conference on Child and Adolescent Cancer Survivorship, April 2016

“Health Risks Associated with the Treatment of Cancer during Childhood and Adolescence”  
Department of Pediatrics Grand Rounds, Harbor-UCLA Medical Center, April 2016

“Heart failure risk reduction in childhood cancer survivors”  
Best of the COG, American Society of Pediatric Hematology/Oncology, May 2016

“Fighting for the heart of the matter in childhood cancer survivors”  
Association of Pediatric Hematology Oncology Nurses, Southern California Chapter, May 2016

“Cardiovascular and metabolic disorders in HCT survivors: blueprint for research”  
Session Co-Chair: NIH BMT Late Effects Consensus Conference, June 2016

“Collaboration to improve the health of childhood cancer survivors”  
Caltech-City of Hope Presidential Symposium, September 2016

“Guidelines in cardio-oncology: where are we now?”  
Global Cardio-Oncology Summit, September 2016

“Cardiac health and long-term follow-up of childhood cancer survivors”  
Congress of the International Society of Pediatric Oncology (SIOP), October 2016

“Cardiovascular disease and cancer: emerging paradigms in biology, prevention, and treatment”  
Duke Clinical Research Institute Research Conference, November 2016

“Cardiovascular disease and cancer survivorship”  
Long Term Effects & Survivorship Affinity Group, Fred Hutchinson Cancer Center, November 2016

“Prevention of cardiovascular disease in survivors of childhood cancer”  
Peckham Center for Cancer & Blood Disorders, Rady Children’s Hospital, January 2017

“Cancer and accelerated aging: emerging paradigms”  
Workshop on Cancer and Aging, UCLA Jonsson Comprehensive Cancer Center, February 2017

“Guideline-driven-care in cardio-oncology: utilizing recommendations across disciplines”

“How we can use biomarkers and genetics to predict toxicity”

Advancing Cardiovascular Care of the Oncology Patient, American College of Cardiology, February 2017

“Late effects of transplants: lessons learned and strategies to improve the health of the HCT survivor”  
How the Experts Treat Hematologic Malignancies, March 2017

## **Curriculum Vitae** **Saro H. Armenian, DO, MPH**

- “Cancer and accelerated aging: Insights into pathophysiology and prevention”  
Education Session, AACR Annual Meeting, April 2017
- “Cardiotoxicity in Adult Survivors of Childhood Cancer”; “Newest ASCO Cardio-Oncology Practice Guideline”  
Memorial Sloan Kettering Cardio-Oncology Symposium, May 2017
- “Health Risks Associated with the Treatment of Cancer during Childhood and Adolescence”  
International Central Nervous System Germ Cell Tumors Conference, June 2017
- “Health Risks Associated with the Treatment of Cancer in Young Adults”  
Stupid Cancer, Southern California Regional Summit, August 2017
- “Long-term effects of bone marrow transplantation”  
Educational Session, Pediatric Blood & Marrow Transplant Consortium Conference, September 2017
- “How to Improve the Health of the Adolescent and Young Adult Cancer Patient”  
City of Hope Continuing Medical Education Series, October 2017
- “Cardiovascular disease and cancer: emerging paradigms in biology, prevention, and treatment”  
Memorial Sloan Kettering Comprehensive Cancer Center, SOAR Seminar, October 2017
- “Emerging Paradigms in Risk Prediction and Prevention of Late Effects”  
Educational session, BMT Tandem Meetings, February 2018
- “Guideline-driven-care in cardio-oncology”; “Cardiovascular Risk Assessment and Cancer Treatment”  
Advancing Cardiovascular Care of the Oncology Patient, American College of Cardiology, February 2018
- “Championing Survivorship through Healthy Living”  
Keynote Speaker, Leukemia & Lymphoma Society, Blood Cancer Conference, March 2018
- “Prevention of late toxicity using clinical trials: A focus on cardiovascular disease”  
Education session, AACR Annual Meeting, April 2017
- “Guideline-directed cardiovascular screening for cancer survivors”  
International colloquium on cardio-oncology, May 2018
- “Prevention Exemplar: Carvedilol in Preventing Heart Failure in Childhood Cancer Survivors”  
“Building the Evidence Base: Guideline Gaps”  
Changing Hearts and Minds: Cancer Treatment-Related Cardiotoxicity, National Cancer Institute, June 2018
- “Cancer and Cardiovascular Disease: Insights into Pathophysiology and Prevention”  
Keynote Speaker, European Cancer Rehabilitation & Survivorship Symposium, September 2018
- “Reconciling Guidelines, Recommendations and Consensus Statements for Optimal Cardio-Oncology Care”  
Plenary Lecture, Global Cardio-Oncology Summit, September 2018
- “Novel mHealth Platform for Detection of Cardiomyopathy in Childhood Cancer Survivors”  
Emerging Technologies in Childhood Cancer Survivorship Research Conference, November 2018
- “Guideline-driven-care across the lifespan”; “CV risk alert in hematologic malignancies”  
Advancing Cardiovascular Care of the Oncology Patient, American College of Cardiology, January 2019
- “Prevention of late toxicity in childhood cancer survivors”  
Keynote Speaker, Childhood Cancer: Research Challenges and the Future of Therapy, March 2019
- “Strategies to optimize the health of childhood cancer survivors”  
Plenary Lecture, Association of Pediatric Hematology Oncology Nurses, Southern California, May 2019
- “Global Application of Risk Stratification in Childhood Cancer Survivors”  
Invited Discussant, American Society of Clinical Oncology, June 2019
- “Interventions to Mitigate Health-Related Complications in Survivors”  
Keynote Speaker, North American Symposium on Late Complications after Childhood Cancer, June 2019

## Curriculum Vitae Saro H. Armenian, DO, MPH

- “CV Disease Risk Scores in Cancer Patients: An Overview of Development and Barriers to Implementation”  
ACC Cardio-Oncology Roundtable, September 2019
- “Cardiovascular Risk Alert in Hematologic Malignancies: Stem Cell Transplant and Cardiotoxic Exposures”  
Global Cardio-Oncology Symposium, October 2019
- “Cardiovascular health and long-term follow-up of childhood cancer survivors”  
Congress of the International Society of Pediatric Oncology, October 2019
- “Cardiovascular disease in survivors of childhood cancer: from etiology to risk reduction strategies”  
Invited Grand Rounds, Maria Fareri Children’s Hospital, November 2019
- “CV Risk Alert in Hematologic Malignancies, Stem Cell Transplantation and Cardiotoxic Exposures”  
Advancing Cardiovascular Care of the Oncology Patient, American College of Cardiology, February 2020
- “Hematopoietic Cell Transplantation Survivors: Phenotypes and Health Conditions to Consider”  
Obesity, Metabolism and Survivorship Symposium; St. Jude Children’s Research Hospital, February 2020
- “Clonal Hematopoiesis and its Impact on Outcomes after Hematopoietic Cell Transplantation”  
V Foundation NYC Science Conference, June 2020
- “Anthracyclines and Cardiovascular Complications”  
1<sup>st</sup> Cardio-Oncology International Virtual Symposium, September 2020
- “Hematopoietic Cell Transplantation Survivors: Unique Phenotypes and Metabolic Disorders to Consider”  
Diabetes and Cancer: Connecting the Dots; City of Hope, November 2020
- “Long-term follow-up strategies in patients with lymphoma”  
Argentine Cardio-Oncology Symposium, November 2020
- “Defining who is at Cardiovascular Risk in Hematologic Malignancies”  
“Cardio-Oncology Clinical Practice Guidelines”  
Advancing Cardiovascular Care of the Oncology Patient, American College of Cardiology, February 2021
- “Consideration of Biologic Aging Across the Spectrum of Cellular Therapy Delivery”  
Education Session, Transplantation & Cellular Therapy Meetings, February 2021
- “Thriving Beyond AYA Cancer: Examples and Opportunities in Cancer Survivorship”  
Keynote Speaker, 11<sup>th</sup> Annual Texas Adolescent and Young Adult Oncology Conference, February 2021
- “Imaging in Surveillance and Advancing Pediatric Cancer Survivorship”  
Danny Thomas Lecture, St Jude Children’s Research Hospital, February 2021
- “Heart Health after Transplantation”  
Keynote Speaker, BMT InfoNet Symposium, April 2021
- “Interventions to Mitigate Cardiovascular Complications in Survivors”  
Educational Session, American Society of Pediatric Hematology Oncology, April 2021
- “Long Term Survivorship after Hematopoietic Stem Cell Transplant with a focus on Cardiovascular Health”  
National Excellence in Cancer Care Symposium, October 2021
- “Cardiometabolic Health and Function after HCT”  
American Society of Transplantation and Cellular Therapy Special Interest Group, November 2021
- “From Birth to Life - the Heart Journey of Cancer Survivorship”  
Main Event, American Heart Association Scientific Sessions, November 2021
- “Cardiovascular disease in survivors of childhood cancer: from etiology to risk reduction strategies”  
Division of Pediatric Hematology/Oncology, Columbia University, February 2022
- “Cancer and Cardiovascular Disease: Emerging Paradigms in Biology, Prevention, and Treatment”  
USC Norris Comprehensive Cancer Center Grand Rounds, May 2022

**Curriculum Vitae**  
**Saro H. Armenian, DO, MPH**

“Cardiovascular Disease in Childhood Cancer Patients and Survivors: Emerging Paradigms to Consider”  
Keynote Speaker, FDA Externally-led Patient-Focused Drug Development Conference, October 2022

“Championing Survivorship Through Healthy Living”  
Keynote Speaker, Hawaii Children's Cancer Foundation, November 2022

“Optimizing the long-term health of childhood and AYA cancer patients & survivors”  
Grand Rounds, Kapi'olani Medical Center for Women and Children, November 2022